[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Alcon Research, LTD.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":343},{"warningLetters":4,"total":342},[5,32,53,74,95,114,126,151,173,193,214,232,250,268,286,303,322],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},3599,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-12T04:00:00Z\">08\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fauriga-research-pvt-ltd-730694-08122026\">Auriga Research Pvt. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-113\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Saurabh Arora\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Auriga Research Pvt. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3\u002F17 Kirti Nagar, Industrial Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Delhi\u003C\u002Fspan> \u003Cspan>110015\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 12, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-26-113\u003C\u002Fp>\u003Cp>To Dr. Saurabh Arora:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your contract testing laboratory. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your contract testing laboratory, Auriga Research Pvt. Ltd., FEI 3019975128, at No. 136, 6th Cross, 2nd Stage, Yeshwanthpur Industrial Suburb, Bengaluru, India, from February 4 to 6, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for the US market. Your laboratory records lacked complete and original data demonstrating that you performed the required testing.\u003C\u002Fp>\u003Cp>You did not accurately complete laboratory records contemporaneously at the time you performed the laboratory activities. Our investigator observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> microbial test samples that lacked complete documentation on raw data test sheets (e.g., the test sheets had blank spaces where entries should have been recorded). While your summary reports included final plate counts, your raw data test sheets for some of the samples covered in these reports lacked complete documentation of plate counts.\u003C\u002Fp>\u003Cp>In your response, you stated these samples were not from drug products intended for the U.S. market. However, your firm maintains one quality system and has one set of procedures for testing U.S. and non-U.S. drug products. Thus, the quality unit (QU) failure is applicable to all drug products you test. Additionally in your response, you identify the documentation deficiencies to be “consistent with an institutional procedural and cultural gap rather than individual misconduct or a coordinated effort to conceal or falsify results.” This indicates that these violative practices are used for all drugs you test, including those for the U.S. market.\u003C\u002Fp>\u003Cp>We acknowledge that your response indicated you will increase the QU presence during testing until procedural improvements, training effectiveness verification, and compliance monitoring demonstrate sustained adherence. Your response is inadequate because it does not include an assessment of your paper-based documentation system to identify and correct vulnerabilities in your current controls. Additionally, you did not provide evidence that you performed a retrospective review to identify any additional instances of incomplete or non-contemporaneous documentation.\u003C\u002Fp>\u003Cp>Microbial testing, an essential quality control step, is integral in preventing distribution of unsafe products. Integrity of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with drug testing. Furthermore, the lack of reliable data compromises the QU’s ability to exercise its function of ensuring compliance with applicable standards.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document\u003Cem> Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\u003Cbr>o unique labeling of each sample\u003Cbr>o signatures of all staff who handle the sample\u003Cbr>o complete tracking of sample integrity and custody\u003Cbr>o date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\u003Cbr>o digital time-stamped photos of all plates\u003Cbr>o signatures of personnel performing reading of microbial counts\u003Cbr>o provisions for verifications and routine quality assurance oversight.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU is inadequate as demonstrated through its oversight of investigations. Your QU reviewed and approved investigations that did not thoroughly investigate unexplained discrepancies or failures of a drug product to meet any of its specifications. For example, your QU failed to adequately ensure root causes were appropriately supported and CAPA were justified and implemented for the following:\u003C\u002Fp>\u003Cul>\u003Cli>Concerning an out-of-specification (OOS) investigation for assay of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, after failing the initial test, hypothesis and two repeat tests, you changed your autotitrator instrument and reported passing results. You failed to scientifically justify the root cause, electrode sensing issue, and your investigation failed to include a CAPA.\u003C\u002Fli>\u003Cli>Concerning an OOS investigation for assay of \u003Cstrong>(b)(4)\u003C\u002Fstrong> after failing the initial test, hypothesis, and five repeat tests, you invalidated all these results. You failed to scientifically justify the root cause, which you attributed as a sample weighing error and insufficient electrode saturation. Your preventive action was inadequate as you only verbally made “concerned analysts” aware.\u003C\u002Fli>\u003Cli>Concerning an OOS investigation for a specified impurity, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in stability samples, you accepted passing results by testing retain samples in triplicate. You failed to scientifically justify the root cause, which you attributed as contamination of the “MS source.” Your preventive action was inadequate as you only instructed the analyst to clean the source before the initiation of the analysis without revising your procedure.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This strategy of using repeated testing until you obtain a passing result, then disregarding the OOS results without scientific justification (“testing into compliance”) is unscientific and objectionable under CGMP.\u003C\u002Fp>\u003Cp>In your response, you state you are revising your OOS investigation procedure to mandate your hypothesis plan with scientific justification. Your response is inadequate because you are revising procedures without performing a gap analysis of your investigations. Additionally, you have failed to address the authority, responsibility, and competency of your QU which had reviewed and approved all your out-of-specification investigations.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also describe how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all OOS including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the U.S. for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history).\u003Cbr>o Provide whether customers were notified of each OOS.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities of a Contract Testing Lab\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP and that you inform all your customers of any out-of-specification results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug testing facility until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured by your clients and tested at Auriga Research Private Limited, Bengaluru, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen 15 business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 3019975128 and ATTN: Compliance Officer Barbara Wilimczyk-Macri in the letter or in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: RD2Rx, LLC\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nReference #:\n\n320-26-113\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Saurabh Arora\n\nRecipient Title\n\nManaging Director and CEO\n\nAuriga Research Pvt. Ltd.\n\n3\u002F17 Kirti Nagar, Industrial Area\n\nNew Delhi 110015\n\nIndia\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nAugust 12, 2026\nWARNING LETTER\nReference number: 320-26-113\nTo Dr. Saurabh Arora:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your contract testing laboratory. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Inspection\nViolations were observed and documented during an inspection of your contract testing laboratory, Auriga Research Pvt. Ltd., FEI 3019975128, at No. 136, 6th Cross, 2nd Stage, Yeshwanthpur Industrial Suburb, Bengaluru, India, from February 4 to 6, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\nYour firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for the US market. Your laboratory records lacked complete and original data demonstrating that you performed the required testing.\nYou did not accurately complete laboratory records contemporaneously at the time you performed the laboratory activities. Our investigator observed (b)(4) microbial test samples that lacked complete documentation on raw data test sheets (e.g., the test sheets had blank spaces where entries should have been recorded). While your summary reports included final plate counts, your raw data test sheets for some of the samples covered in these reports lacked complete documentation of plate counts.\nIn your response, you stated these samples were not from drug products intended for the U.S. market. However, your firm maintains one quality system and has one set of procedures for testing U.S. and non-U.S. drug products. Thus, the quality unit (QU) failure is applicable to all drug products you test. Additionally in your response, you identify the documentation deficiencies to be “consistent with an institutional procedural and cultural gap rather than individual misconduct or a coordinated effort to conceal or falsify results.” This indicates that these violative practices are used for all drugs you test, including those for the U.S. market.\nWe acknowledge that your response indicated you will increase the QU presence during testing until procedural improvements, training effectiveness verification, and compliance monitoring demonstrate sustained adherence. Your response is inadequate because it does not include an assessment of your paper-based documentation system to identify and correct vulnerabilities in your current controls. Additionally, you did not provide evidence that you performed a retrospective review to identify any additional instances of incomplete or non-contemporaneous documentation.\nMicrobial testing, an essential quality control step, is integral in preventing distribution of unsafe products. Integrity of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with drug testing. Furthermore, the lack of reliable data compromises the QU’s ability to exercise its function of ensuring compliance with applicable standards.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uninterrupted custody and full reconciliation of all microbiological samples, including but not limited to:\no unique labeling of each sample\no signatures of all staff who handle the sample\no complete tracking of sample integrity and custody\no date and time of each activity (e.g., sample collection, delivery, incubation, removal from incubator)\no digital time-stamped photos of all plates\no signatures of personnel performing reading of microbial counts\no provisions for verifications and routine quality assurance oversight.\n2. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour QU is inadequate as demonstrated through its oversight of investigations. Your QU reviewed and approved investigations that did not thoroughly investigate unexplained discrepancies or failures of a drug product to meet any of its specifications. For example, your QU failed to adequately ensure root causes were appropriately supported and CAPA were justified and implemented for the following:\nConcerning an out-of-specification (OOS) investigation for assay of (b)(4), after failing the initial test, hypothesis and two repeat tests, you changed your autotitrator instrument and reported passing results. You failed to scientifically justify the root cause, electrode sensing issue, and your investigation failed to include a CAPA.\nConcerning an OOS investigation for assay of (b)(4) after failing the initial test, hypothesis, and five repeat tests, you invalidated all these results. You failed to scientifically justify the root cause, which you attributed as a sample weighing error and insufficient electrode saturation. Your preventive action was inadequate as you only verbally made “concerned analysts” aware.\nConcerning an OOS investigation for a specified impurity, (b)(4), in stability samples, you accepted passing results by testing retain samples in triplicate. You failed to scientifically justify the root cause, which you attributed as contamination of the “MS source.” Your preventive action was inadequate as you only instructed the analyst to clean the source before the initiation of the analysis without revising your procedure.\nThis strategy of using repeated testing until you obtain a passing result, then disregarding the OOS results without scientific justification (“testing into compliance”) is unscientific and objectionable under CGMP.\nIn your response, you state you are revising your OOS investigation procedure to mandate your hypothesis plan with scientific justification. Your response is inadequate because you are revising procedures without performing a gap analysis of your investigations. Additionally, you have failed to address the authority, responsibility, and competency of your QU which had reviewed and approved all your out-of-specification investigations.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also describe how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decision authority, and is fully supported by executive management.\nA retrospective, independent review of all OOS including in-process and release\u002Fstability testing) results for U.S. products irrespective of whether the batch was ultimately distributed in the U.S. for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history).\no Provide whether customers were notified of each OOS.\nResponsibilities of a Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your clients. It is essential that you understand your responsibility to operate in full compliance with CGMP and that you inform all your customers of any out-of-specification results or significant problems encountered during the testing of these drugs.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA may withhold approval of new applications or supplements listing your firm as a drug testing facility until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured by your clients and tested at Auriga Research Private Limited, Bengaluru, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen 15 business days of receipt of this letter1. Identify your written response with FEI 3019975128 and ATTN: Compliance Officer Barbara Wilimczyk-Macri in the letter or in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: RD2Rx, LLC\n(b)(4)\n_____________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Auriga Research Pvt. Ltd.","auriga-research-pvt-ltd-730694-08122026","2026-08-19T04:06:48.349905+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fauriga-research-pvt-ltd-730694-08122026","2026-10-26T08:07:59.09443+00:00","Warning Letter","Issued","2026-08-18","730694","Drugs","Dr. Saurabh Arora","2026-08-19T04:07:02.207+00:00","VIA UNITED PARCEL SERVICE","320-26-113","2026-08-12",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1132,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2024-12-17T14:20:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-10T05:00:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxcel-research-llc-694608-12102024\">Xcel Research LLC\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded ","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew Pierce\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Xcel Research LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1309 Coffeen Ave., Suite 12238\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sheridan\u003C\u002Fspan>, \u003Cspan>WY\u003C\u002Fspan> \u003Cspan>82801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Support@XcelPeptides.com\"> Support@XcelPeptides.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>\u003Cu>WARNING LETTER\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 10, 2024\u003C\u002Fp>\u003Cp>RE: 694608\u003C\u002Fp>\u003Cp>Dear Andrew Pierce:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” for sale in the United States. As described below, your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products, “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>“RETA” (Retatrutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Freta\u002F:\u003Cbr>• “Retatrutide, a triple agonist peptide, interacts with glucagon, GIP, and GLP-1 receptors. In clinical trials, it exhibits potential for weight management by regulating appetite and metabolism in research test subjects.”\u003Cbr>• “Enhanced Insulin Sensitivity . . . By enhancing insulin sensitivity, retatrutide peptide helps test subjects maintain stable blood glucose levels and reduces the risk of developing metabolic disorders associated with insulin resistance.”\u003Cbr>• “Cardiovascular Protection . . . [R]etatrutide peptide has been shown to improve endothelial function, reduce arterial stiffness, and lower blood pressure, thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“CagriLean” (Cagrilintide and Semaglutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilean\u002F:\u003Cbr>• “Cagrilintide and semaglutide blend that aids test subjects in managing weight and improving blood sugar levels. This peptide combination helps research subjects feel fuller for longer, curbing their appetite and enhancing metabolic function.”\u003Cbr>• “Understanding Cagrilintide and Semaglutide . . . Cagrilintide is a synthetic peptide known for its ability to regulate appetite. It mimics the natural hormone amylin, which plays a crucial role in controlling hunger and food intake. On the other hand, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It has been extensively researched for its effects on glucose regulation and appetite suppression.”\u003Cbr>• “Enhanced Glucose Regulation . . . CagriLean helps maintain stable blood glucose levels, reducing the risk of glucose spikes and crashes. This can be instrumental in experiments focusing on insulin sensitivity, glucose metabolism, and the development of diabetes treatments.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“CAGRILINTIDE”\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilintide\u002F:\u003Cbr>• “Enhanced Glucose Control . . . By influencing the release of insulin and other hormones involved in glucose metabolism, it may help stabilize blood sugar levels. This effect could be beneficial for research test subjects with conditions such as diabetes or insulin resistance.”\u003Cbr>• “Improved Lipid Profile: Research suggests that Cagrilintide may also have favorable effects on lipid metabolism, leading to improvements in lipid profiles. By influencing the breakdown and utilization of fats, it may help lower levels of triglycerides and LDL cholesterol while increasing HDL cholesterol levels.”\u003Cbr>• “Cagrilintide exhibits a wide range of potential health benefits for research test subjects, spanning appetite regulation, glucose control, weight management, lipid metabolism, inflammation, cardiometabolic protection, neuroprotection, and the convenience of long-acting formulation.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“MAZDUTIDE”&nbsp;\u003C\u002Fstrong>&nbsp;\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fmazdutide\u002F:\u003Cbr>• “Mazdutide. . .[is] designed to mimic the actions of a hormone called glucagon-like peptide-1 (GLP-1). It offers numerous benefits in research subjects, such as improving blood sugar control by stimulating insulin secretion and reducing appetite. Additionally, it aids in weight management and may enhance cardiovascular health by lowering blood pressure and improving cholesterol levels.”\u003Cbr>• “Cardiovascular Health: Mazdutide exhibits cardioprotective effects, which could be advantageous for research test subjects at risk of cardiovascular diseases. GLP-1 receptor activation has been linked to improvements in cardiovascular function, such as reducing blood pressure and improving lipid profiles.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“SEMA” (Semaglutide)\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsema\u002F:\u003Cbr>• “Regulation of Blood Sugar Levels: Sema exhibits potent glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release, two crucial mechanisms in maintaining blood sugar balance.”\u003Cbr>• “Weight Loss and Appetite Suppression: . . . By acting on specific receptors in the brain, this peptide promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”\u003Cbr>• “Neuroprotective Potential: Emerging evidence suggests that semaglutide peptide may possess neuroprotective properties, offering potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”\u003C\u002Fp>\u003Cp>\u003Cstrong>“SURVODUTIDE”\u003C\u002Fstrong>\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\u003Cbr>• “Survodutide. . .belongs to a class of drugs known as dual agonists, meaning it targets two different types of receptors in the body: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors play crucial roles in regulating various bodily functions, including metabolism, appetite, and blood sugar levels.”\u003Cbr>• “Health Benefits of Survodutide . . . Improved Blood Sugar Control[.] One of the most significant benefits of survodutide is its ability to improve blood sugar control in research lab subjects . . .. [I]t can help regulate blood glucose levels more effectively than targeting either receptor alone. In research subjects, this dual action has shown promise in stabilizing blood sugar levels, which is crucial for managing conditions like diabetes.\"\u003C\u002Fp>\u003Cp>\u003Cstrong>“SERMORELIN”&nbsp;\u003C\u002Fstrong>&nbsp;\u003Cbr>On your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsermorelin\u002F:\u003Cbr>• “Sermorelin, a peptide studied in clinical trials, is believed to enhance the release of growth hormone in subjects. This heightened growth hormone production is associated with potential benefits, including improved metabolism and the facilitation of weight loss.”\u003Cbr>• “Enhanced Muscle Growth and Repair[.] One of the primary benefits observed in test subjects administered with sermorelin is enhanced muscle growth and repair.”\u003Cbr>• “Improved Metabolism and Fat Loss[.] Another notable benefit of sermorelin is its potential to improve metabolism and aid in fat loss.”\u003C\u002Fp>\u003Cp>Your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAndrew Pierce\n\nXcel Research LLC\n\n1309 Coffeen Ave., Suite 12238\n\nSheridan, WY 82801\n\nUnited States\n\nSupport@XcelPeptides.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 10, 2024\nRE: 694608\nDear Andrew Pierce:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” for sale in the United States. As described below, your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nDespite statements on your product labeling marketing your products, “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\n“RETA” (Retatrutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Freta\u002F:\n• “Retatrutide, a triple agonist peptide, interacts with glucagon, GIP, and GLP-1 receptors. In clinical trials, it exhibits potential for weight management by regulating appetite and metabolism in research test subjects.”\n• “Enhanced Insulin Sensitivity . . . By enhancing insulin sensitivity, retatrutide peptide helps test subjects maintain stable blood glucose levels and reduces the risk of developing metabolic disorders associated with insulin resistance.”\n• “Cardiovascular Protection . . . [R]etatrutide peptide has been shown to improve endothelial function, reduce arterial stiffness, and lower blood pressure, thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis.”\n“CagriLean” (Cagrilintide and Semaglutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilean\u002F:\n• “Cagrilintide and semaglutide blend that aids test subjects in managing weight and improving blood sugar levels. This peptide combination helps research subjects feel fuller for longer, curbing their appetite and enhancing metabolic function.”\n• “Understanding Cagrilintide and Semaglutide . . . Cagrilintide is a synthetic peptide known for its ability to regulate appetite. It mimics the natural hormone amylin, which plays a crucial role in controlling hunger and food intake. On the other hand, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It has been extensively researched for its effects on glucose regulation and appetite suppression.”\n• “Enhanced Glucose Regulation . . . CagriLean helps maintain stable blood glucose levels, reducing the risk of glucose spikes and crashes. This can be instrumental in experiments focusing on insulin sensitivity, glucose metabolism, and the development of diabetes treatments.”\n“CAGRILINTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fcagrilintide\u002F:\n• “Enhanced Glucose Control . . . By influencing the release of insulin and other hormones involved in glucose metabolism, it may help stabilize blood sugar levels. This effect could be beneficial for research test subjects with conditions such as diabetes or insulin resistance.”\n• “Improved Lipid Profile: Research suggests that Cagrilintide may also have favorable effects on lipid metabolism, leading to improvements in lipid profiles. By influencing the breakdown and utilization of fats, it may help lower levels of triglycerides and LDL cholesterol while increasing HDL cholesterol levels.”\n• “Cagrilintide exhibits a wide range of potential health benefits for research test subjects, spanning appetite regulation, glucose control, weight management, lipid metabolism, inflammation, cardiometabolic protection, neuroprotection, and the convenience of long-acting formulation.”\n“MAZDUTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fmazdutide\u002F:\n• “Mazdutide. . .[is] designed to mimic the actions of a hormone called glucagon-like peptide-1 (GLP-1). It offers numerous benefits in research subjects, such as improving blood sugar control by stimulating insulin secretion and reducing appetite. Additionally, it aids in weight management and may enhance cardiovascular health by lowering blood pressure and improving cholesterol levels.”\n• “Cardiovascular Health: Mazdutide exhibits cardioprotective effects, which could be advantageous for research test subjects at risk of cardiovascular diseases. GLP-1 receptor activation has been linked to improvements in cardiovascular function, such as reducing blood pressure and improving lipid profiles.”\n“SEMA” (Semaglutide)\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsema\u002F:\n• “Regulation of Blood Sugar Levels: Sema exhibits potent glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release, two crucial mechanisms in maintaining blood sugar balance.”\n• “Weight Loss and Appetite Suppression: . . . By acting on specific receptors in the brain, this peptide promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”\n• “Neuroprotective Potential: Emerging evidence suggests that semaglutide peptide may possess neuroprotective properties, offering potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”\n“SURVODUTIDE”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\n• “Survodutide. . .belongs to a class of drugs known as dual agonists, meaning it targets two different types of receptors in the body: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors play crucial roles in regulating various bodily functions, including metabolism, appetite, and blood sugar levels.”\n• “Health Benefits of Survodutide . . . Improved Blood Sugar Control[.] One of the most significant benefits of survodutide is its ability to improve blood sugar control in research lab subjects . . .. [I]t can help regulate blood glucose levels more effectively than targeting either receptor alone. In research subjects, this dual action has shown promise in stabilizing blood sugar levels, which is crucial for managing conditions like diabetes.\"\n“SERMORELIN”\nOn your webpage https:\u002F\u002Fwww.xcelpeptides.com\u002Fproduct\u002Fsermorelin\u002F:\n• “Sermorelin, a peptide studied in clinical trials, is believed to enhance the release of growth hormone in subjects. This heightened growth hormone production is associated with potential benefits, including improved metabolism and the facilitation of weight loss.”\n• “Enhanced Muscle Growth and Repair[.] One of the primary benefits observed in test subjects administered with sermorelin is enhanced muscle growth and repair.”\n• “Improved Metabolism and Fat Loss[.] Another notable benefit of sermorelin is its potential to improve metabolism and aid in fat loss.”\nYour “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Xcel Research LLC","xcel-research-llc-694608-12102024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxcel-research-llc-694608-12102024","2026-10-26T08:10:34.731468+00:00","2024-12-17","694608","Andrew Pierce","2026-08-19T17:08:28.221+00:00","Via Email","2024-12-10",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2921,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-18T05:00:00Z\">11\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeronova-research-inc-612777-11182021\">GeroNova Research Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations - West Division 5","Internet Marketing of Unapproved and Misbranded Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Karyn Young\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GeroNova Research Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2600 Hilltop Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bldg B, Ste C120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations - West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nWL 612777\u003C\u002Fp>\n\n\u003Cp>November 18, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Karyn Young:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your Amazon.com store, which operates under the name GeroNova Research Inc., in September to October 2021 and has determined that you take orders there for the products CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir (also referred to as Liquid L-Carnitine and Liquid CARNITINE-PLUS), R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg. We also reviewed your social media websites at www.facebook.com\u002FGeroNovaResearch and www.twitter.com\u002Fgeronova, both of which direct consumers to your website www.geronova.com, which directs consumers to your Amazon.com store to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On your Facebook page, https:\u002F\u002Fwww.facebook.com\u002FGeroNovaResearch\u002F, from a February 20, 2018 post entitled “Exciting News in the World of #Carnitine!”, which discusses carnitine, an ingredient in CARNITINE PLUS Vegcaps and GeroNova Beauté Infinie Elixir, and hyperlinks to the CARNITINE PLUS Vegcaps page of your website www.geronova.com, which contains a “Buy on Amazon” button that directs consumers to your Amazon.com store to purchase this product:\u003C\u002Fp>\n\n\u003Cp>• “For example, research demonstrated that mitochondrial dysfunction, aging, autism, cardiomyopathy, many errors in metabolism, dislipidemia, and renal disease are among just a few of the remarkable clinical areas in which the addition of carnitine supplementation demonstrated an essential role in improved outcomes.”\u003Cbr>\n• “A systematic review and meta-analysis that investigated the effect of supplemental Acetyl-L-Carnitine (do not confuse with other forms of carnitine) on ‘depressive symptoms across randomized controlled trials’ concluded that supplemental Acetyl-L-Carnitine: \u003Cem>‘significantly decreases depressive symptoms compared with placebo\u002Fno intervention, while offering a comparable effect with that of established antidepressant agents with fewer adverse effects.’”\u003C\u002Fem>\u003Cbr>\n• “In fascinating Parkinson's disease pre-clinical research modeling, Acetyl-L-Carnitine improved cognitive function, extended neuronal survival and modulated key imbalances between cytokines.”\u003C\u002Fp>\n\n\u003Cp>On your Facebook page, https:\u002F\u002Fwww.facebook.com\u002FGeroNovaResearch\u002F, from a September 1, 2018 post entitled “While Pharma Industry Scrambles for the Fountain-of-Youth, New Research Demonstrates Again: Anti-Aging is Available Right Now!”:\u003Cbr>\n• “[R]esearch demonstrated that acetyl-l-carnitine [an ingredient in your CARNITINE PLUS Vegcaps] supplementation inhibited insulin resistance through AMPK stimulation… acetyl-l-carnitine administration: Restored Sirtuin-3 activity . . .”\u003Cbr>\n• “A key cardio-protective area involved R-Lipoic Acid’s [an ingredient in your R-Lipoic Acid Vegcaps 300 mg and R-Lipoic Acid Vegcaps 100 mg] ability to improve a pivotal pathological disease-state (called endothelial dysfunction) through several mechanisms, including the ability to increase AMPK. [footnote omitted] Cumulative research also revealed R-Lipoic Acid’s established ability to …\u003Cbr>\n&nbsp; o ‘Possess anti-diabetic and anti-obesity properties,’ [footnote omitted] as it both increases insulin sensitivity through AMPK activation [footnote omitted] and a reduces insulin in pancreatic beta cells [footnote omitted]\u003Cbr>\n&nbsp; o Improve mitochondrial function in Nonalcoholic Steatosis (liver disease) by stimulating Sirtuin-1 and Sirtuin-3 proteins [footnote omitted]”\u003Cbr>\n• “Did you know that the body naturally produces impressive anti-aging compounds such as ‘sirtuins’ and ‘AMP Kinase (AMPK) [which you claim are increased or stimulated by R-Lipoic Acid and acetyl-l-carnitine]?’ Cumulative research established that these proteins set off a cascade of crucial functions in the body, including…Anti-tumor effect…What is more, research demonstrated that a reduction in sirtuins was associated with aggressive disease-states such as diabetes and insulin resistance…Equally as important, a reduction in AMPK was associated with cardiomyopathy…”\u003C\u002Fp>\n\n\u003Cp>On your Twitter page, www.twitter.com\u002Fgeronova:\u003Cbr>\n• You retweeted another user’s October 6, 2018 tweet, which said, “Carnitine [an ingredient in CARNITINE PLUS Vegcaps and GeroNova Beauté Infinie Elixir] does so much in this one. #diabetes . . .” and retweeted the following tweet you posted on July 27, 2018: “Key to energy production, new research study shows “#carnitine supplementation stabilises hyperglycaemia and increases the metabolism of pyruvate in the diabetic heart. l-carnitine provides a means to improve pyruvate metabolism in the #diabetic heart . . .”\u003Cbr>\n• You retweeted another user’s September 26, 2014 tweet, which said, “#lipoicacid [an ingredient in your R-Lipoic Acid Vegcaps 300 mg and R-Lipoic Acid Vegcaps 100 mg] model treats autonomic neuropathy… @geronova is the best! I’ve tried it.”\u003C\u002Fp>\n\n\u003Cp>On your Amazon.com product page for CARNITINE PLUS Vegcaps, https:\u002F\u002Fwww.amazon.com\u002Fgeronova-research-carnitine-supplement-effective\u002Fdp\u002FB08KS1SF36\u002Fref=sr_1_5?dchild=1&amp;keywords=carnitine+plus&amp;qid=1634152800&amp;sr=8-5:\u003Cbr>\n• “IMPROVE BLOOD SUGAR LEVELS: Studies have shown that L-carnitine … while improving insulin resistance.*”\u003C\u002Fp>\n\n\u003Cp>On your Amazon.com product page for GeroNova Beauté Infinie Elixir, https:\u002F\u002Fwww.amazon.com\u002FL-Carnitine-Absorption-Magnesium-Metabolism-Supplements\u002Fdp\u002FB08L3W3VMP\u002Fref=sr_1_1?dchild=1&amp;keywords=l+carnitine+liquid&amp;qid=1633638420&amp;refinements=p_78%3AB08L3W3VMP&amp;sr=8-1:\u003Cbr>\n• “IMPROVE BLOOD SUGAR LEVELS: Studies have shown that L-carnitine … while improving insulin resistance.*”\u003Cbr>\n• “. . . slows signs of . . . cardiovascular and neurological disorders”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003Cbr>\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003Cbr>\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir, R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir, R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Food Operations - West Division 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Or via email to ORAHAFWEST5FirmResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 612777 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at clarice.ahn@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations - West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKaryn Young\n\nRecipient Title\n\nPresident\n\nGeroNova Research Inc.\n\n2600 Hilltop Dr\n\nBldg B, Ste C120\n\nRichmond, CA 94806\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations - West Division 5\n\nUnited States\n\nWARNING LETTER\n\nWL 612777\n\nNovember 18, 2021\n\nDear Karyn Young:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your Amazon.com store, which operates under the name GeroNova Research Inc., in September to October 2021 and has determined that you take orders there for the products CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir (also referred to as Liquid L-Carnitine and Liquid CARNITINE-PLUS), R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg. We also reviewed your social media websites at www.facebook.com\u002FGeroNovaResearch and www.twitter.com\u002Fgeronova, both of which direct consumers to your website www.geronova.com, which directs consumers to your Amazon.com store to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your Facebook page, https:\u002F\u002Fwww.facebook.com\u002FGeroNovaResearch\u002F, from a February 20, 2018 post entitled “Exciting News in the World of #Carnitine!”, which discusses carnitine, an ingredient in CARNITINE PLUS Vegcaps and GeroNova Beauté Infinie Elixir, and hyperlinks to the CARNITINE PLUS Vegcaps page of your website www.geronova.com, which contains a “Buy on Amazon” button that directs consumers to your Amazon.com store to purchase this product:\n\n• “For example, research demonstrated that mitochondrial dysfunction, aging, autism, cardiomyopathy, many errors in metabolism, dislipidemia, and renal disease are among just a few of the remarkable clinical areas in which the addition of carnitine supplementation demonstrated an essential role in improved outcomes.”\n\n• “A systematic review and meta-analysis that investigated the effect of supplemental Acetyl-L-Carnitine (do not confuse with other forms of carnitine) on ‘depressive symptoms across randomized controlled trials’ concluded that supplemental Acetyl-L-Carnitine: ‘significantly decreases depressive symptoms compared with placebo\u002Fno intervention, while offering a comparable effect with that of established antidepressant agents with fewer adverse effects.’”\n\n• “In fascinating Parkinson's disease pre-clinical research modeling, Acetyl-L-Carnitine improved cognitive function, extended neuronal survival and modulated key imbalances between cytokines.”\n\nOn your Facebook page, https:\u002F\u002Fwww.facebook.com\u002FGeroNovaResearch\u002F, from a September 1, 2018 post entitled “While Pharma Industry Scrambles for the Fountain-of-Youth, New Research Demonstrates Again: Anti-Aging is Available Right Now!”:\n\n• “[R]esearch demonstrated that acetyl-l-carnitine [an ingredient in your CARNITINE PLUS Vegcaps] supplementation inhibited insulin resistance through AMPK stimulation… acetyl-l-carnitine administration: Restored Sirtuin-3 activity . . .”\n\n• “A key cardio-protective area involved R-Lipoic Acid’s [an ingredient in your R-Lipoic Acid Vegcaps 300 mg and R-Lipoic Acid Vegcaps 100 mg] ability to improve a pivotal pathological disease-state (called endothelial dysfunction) through several mechanisms, including the ability to increase AMPK. [footnote omitted] Cumulative research also revealed R-Lipoic Acid’s established ability to …\n\no ‘Possess anti-diabetic and anti-obesity properties,’ [footnote omitted] as it both increases insulin sensitivity through AMPK activation [footnote omitted] and a reduces insulin in pancreatic beta cells [footnote omitted]\n\no Improve mitochondrial function in Nonalcoholic Steatosis (liver disease) by stimulating Sirtuin-1 and Sirtuin-3 proteins [footnote omitted]”\n\n• “Did you know that the body naturally produces impressive anti-aging compounds such as ‘sirtuins’ and ‘AMP Kinase (AMPK) [which you claim are increased or stimulated by R-Lipoic Acid and acetyl-l-carnitine]?’ Cumulative research established that these proteins set off a cascade of crucial functions in the body, including…Anti-tumor effect…What is more, research demonstrated that a reduction in sirtuins was associated with aggressive disease-states such as diabetes and insulin resistance…Equally as important, a reduction in AMPK was associated with cardiomyopathy…”\n\nOn your Twitter page, www.twitter.com\u002Fgeronova:\n\n• You retweeted another user’s October 6, 2018 tweet, which said, “Carnitine [an ingredient in CARNITINE PLUS Vegcaps and GeroNova Beauté Infinie Elixir] does so much in this one. #diabetes . . .” and retweeted the following tweet you posted on July 27, 2018: “Key to energy production, new research study shows “#carnitine supplementation stabilises hyperglycaemia and increases the metabolism of pyruvate in the diabetic heart. l-carnitine provides a means to improve pyruvate metabolism in the #diabetic heart . . .”\n\n• You retweeted another user’s September 26, 2014 tweet, which said, “#lipoicacid [an ingredient in your R-Lipoic Acid Vegcaps 300 mg and R-Lipoic Acid Vegcaps 100 mg] model treats autonomic neuropathy… @geronova is the best! I’ve tried it.”\n\nOn your Amazon.com product page for CARNITINE PLUS Vegcaps, https:\u002F\u002Fwww.amazon.com\u002Fgeronova-research-carnitine-supplement-effective\u002Fdp\u002FB08KS1SF36\u002Fref=sr_1_5?dchild=1&keywords=carnitine+plus&qid=1634152800&sr=8-5:\n\n• “IMPROVE BLOOD SUGAR LEVELS: Studies have shown that L-carnitine … while improving insulin resistance.*”\n\nOn your Amazon.com product page for GeroNova Beauté Infinie Elixir, https:\u002F\u002Fwww.amazon.com\u002FL-Carnitine-Absorption-Magnesium-Metabolism-Supplements\u002Fdp\u002FB08L3W3VMP\u002Fref=sr_1_1?dchild=1&keywords=l+carnitine+liquid&qid=1633638420&refinements=p_78%3AB08L3W3VMP&sr=8-1:\n\n• “IMPROVE BLOOD SUGAR LEVELS: Studies have shown that L-carnitine … while improving insulin resistance.*”\n\n• “. . . slows signs of . . . cardiovascular and neurological disorders”\n\nUnapproved New Drugs\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir, R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your CARNITINE PLUS Vegcaps, GeroNova Beauté Infinie Elixir, R-Lipoic Acid Vegcaps 300 mg, and R-Lipoic Acid Vegcaps 100 mg products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Food Operations - West Division 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nOr via email to ORAHAFWEST5FirmResponses@fda.hhs.gov.\n\nRefer to Unique Identification Number 612777 when replying.\n\nIf you have any questions regarding this letter, please contact Clarice J. Ahn, Compliance Officer, at clarice.ahn@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations - West Division 5","GeroNova Research Inc.","geronova-research-inc-612777-11182021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgeronova-research-inc-612777-11182021","2026-10-26T08:08:45.703804+00:00","2022-01-18","612777","Karyn Young","2026-08-20T02:15:47.802+00:00","United Parcel Service","2021-11-18",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":19,"issuing_office":80,"recipient_name":92,"body_fetched_at":93,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1889,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2023-08-29T13:20:00Z\">08\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-16T04:00:00Z\">08\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fessential-research-llc-665098-08162023\">Essential Research, LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Amadeus Benitez, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Arek Schmocker, CFO, COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Essential Research, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@essentialresearchllc.com\"> info@essentialresearchllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 16, 2023\u003C\u002Fp>\n\n\u003Cp>Re: 665098\u003C\u002Fp>\n\n\u003Cp>Dear Amadeus Benitez and Arek Schmocker:\u003C\u002Fp>\n\n\u003Cp>In July 2023, the United States Food and Drug Administration (FDA) reviewed your social media pages and your website, www.chocolaterescuefordogs.com where you offer the product “Chocolate Rescue for Dogs” for sale in the United States. Based on our review, your product is an unapproved new animal drug. As discussed below, marketing an unapproved new animal drug violates the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>The claims on your websites establish that your product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\u003C\u002Fp>\n\n\u003Cp>Chocolate contains components that can be poisonous to dogs. Its ingestion by dogs can potentially cause a life-threatening emergency requiring immediate attention by a veterinarian. Your product, which claims to treat this issue, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\u003C\u002Fp>\n\n\u003Cp>Your product’s name “Chocolate Rescue for Dogs” indicates it is for use in treating (“rescuing”) dogs, who may experience serious adverse health events caused by ingesting chocolate.\u003C\u002Fp>\n\n\u003Cp>Additional examples of claims on your websites and social media webpages that establish these intended uses of your product include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your webpage titled “Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com:\u003Cbr>\n• “Chocolate Rescue for Dogs quickly and efficiently encapsulates the toxins in chocolate — the encapsulated toxins safely pass through your dog's digestive system. The active ingredients specifically affect the toxins but remain unreactive to other molecules, so there are few, if any, side effects.”\u003Cbr>\n• “Within seconds, Chocolate Rescue for Dogs will start absorbing and encapsulating the toxins.”\u003C\u002Fp>\n\n\u003Cp>On your Chocolate Rescue for Dogs product webpage at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fproducts\u002Fchocolate-rescue-for-dogs:\u003Cbr>\n• “…at-home remedy for chocolate ingestion in dogs. The beef soft-chew is safe, effective…”\u003C\u002Fp>\n\n\u003Cp>On your webpage titled “Veterinarians – Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fpages\u002Ffor-veterinarians:\u003Cbr>\n• “The active ingredients quickly push away saliva and other non-toxic molecules, targeting only theobromine and caffeine, allowing a much smaller dose to bind the toxins. As a result, there exists no risk of aspirational pneumonia or intestinal blockage. Most notably, dogs will eat the palatable treat willingly, and at only 7 grams, even a dog with a little appetite can easily be given the potentially lifesaving ‘treat.’”\u003Cbr>\n• “Chocolate Rescue is extremely effective in permanently encapsulating caffeine and theobromine. The product uses a specially-formulated combination of ingredients that instantly draws the free toxins out of the chyme before they can be absorbed. Further, there are millions of binding sites in each dose of Chocolate Rescue, meaning that one chew will effectively nullify large quantities of high-concentration chocolate in a dog's stomach.”\u003C\u002Fp>\n\n\u003Cp>On your blog post titled “Goodwill about Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fblogs\u002Fnews:\u003Cbr>\n• “We are very excited about our product and possibly the end of chocolate toxicosis in dogs!”\u003C\u002Fp>\n\n\u003Cp>On your social media webpages at the URLs https:\u002F\u002Fwww.facebook.com\u002Fp\u002FChocolate-Rescue-for-Dogs-100087135855031\u002F and https:\u002F\u002Fwww.instagram.com\u002Fcr4dogs\u002F:\u003Cbr>\n• On your May 24, 2023, Facebook post: “Thanks to \u003Cstrong>(b)(6)\u003C\u002Fstrong> for eating chocolate, giving us the idea to develop a cure!”\u003Cbr>\n• On your November 29, 2022, Facebook and Instagram posts: “Curious about how Chocolate Rescue for Dogs works?” The post contains an infographic that states: “Chocolate Rescue for Dogs quickly and efficiently encapsulates the toxins in chocolate — the encapsulated toxins safely pass through your dog's digestive system. The active ingredients specifically affect the toxins but remain unreactive to other molecules, so there are few, if any, side effects.”\u003C\u002Fp>\n\n\u003Cp>Your “Chocolate Rescue for Dogs” product is a “new animal drug” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, or 572 of the FD&amp;C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. Your “Chocolate Rescue for Dogs” product is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listed by the FDA, and therefore is considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 665098” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>Cc: info@chocolaterescuefordogs.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nAmadeus Benitez, CEO\n\nRecipient Title\n\nArek Schmocker, CFO, COO\n\nEssential Research, LLC\n\n(b)(6)\n\nUnited States\n\ninfo@essentialresearchllc.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nAugust 16, 2023\n\nRe: 665098\n\nDear Amadeus Benitez and Arek Schmocker:\n\nIn July 2023, the United States Food and Drug Administration (FDA) reviewed your social media pages and your website, www.chocolaterescuefordogs.com where you offer the product “Chocolate Rescue for Dogs” for sale in the United States. Based on our review, your product is an unapproved new animal drug. As discussed below, marketing an unapproved new animal drug violates the Federal Food, Drug, and Cosmetic Act (FD&C Act).\n\nThe claims on your websites establish that your product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal.\n\nChocolate contains components that can be poisonous to dogs. Its ingestion by dogs can potentially cause a life-threatening emergency requiring immediate attention by a veterinarian. Your product, which claims to treat this issue, has not been determined by FDA to be safe and effective. Your unproven treatment could cause animal owners to forgo or delay appropriate veterinary care.\n\nYour product’s name “Chocolate Rescue for Dogs” indicates it is for use in treating (“rescuing”) dogs, who may experience serious adverse health events caused by ingesting chocolate.\n\nAdditional examples of claims on your websites and social media webpages that establish these intended uses of your product include, but are not limited to, the following:\n\nOn your webpage titled “Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com:\n\n• “Chocolate Rescue for Dogs quickly and efficiently encapsulates the toxins in chocolate — the encapsulated toxins safely pass through your dog's digestive system. The active ingredients specifically affect the toxins but remain unreactive to other molecules, so there are few, if any, side effects.”\n\n• “Within seconds, Chocolate Rescue for Dogs will start absorbing and encapsulating the toxins.”\n\nOn your Chocolate Rescue for Dogs product webpage at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fproducts\u002Fchocolate-rescue-for-dogs:\n\n• “…at-home remedy for chocolate ingestion in dogs. The beef soft-chew is safe, effective…”\n\nOn your webpage titled “Veterinarians – Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fpages\u002Ffor-veterinarians:\n\n• “The active ingredients quickly push away saliva and other non-toxic molecules, targeting only theobromine and caffeine, allowing a much smaller dose to bind the toxins. As a result, there exists no risk of aspirational pneumonia or intestinal blockage. Most notably, dogs will eat the palatable treat willingly, and at only 7 grams, even a dog with a little appetite can easily be given the potentially lifesaving ‘treat.’”\n\n• “Chocolate Rescue is extremely effective in permanently encapsulating caffeine and theobromine. The product uses a specially-formulated combination of ingredients that instantly draws the free toxins out of the chyme before they can be absorbed. Further, there are millions of binding sites in each dose of Chocolate Rescue, meaning that one chew will effectively nullify large quantities of high-concentration chocolate in a dog's stomach.”\n\nOn your blog post titled “Goodwill about Chocolate Rescue for Dogs” at the URL https:\u002F\u002Fwww.chocolaterescuefordogs.com\u002Fblogs\u002Fnews:\n\n• “We are very excited about our product and possibly the end of chocolate toxicosis in dogs!”\n\nOn your social media webpages at the URLs https:\u002F\u002Fwww.facebook.com\u002Fp\u002FChocolate-Rescue-for-Dogs-100087135855031\u002F and https:\u002F\u002Fwww.instagram.com\u002Fcr4dogs\u002F:\n\n• On your May 24, 2023, Facebook post: “Thanks to (b)(6) for eating chocolate, giving us the idea to develop a cure!”\n\n• On your November 29, 2022, Facebook and Instagram posts: “Curious about how Chocolate Rescue for Dogs works?” The post contains an infographic that states: “Chocolate Rescue for Dogs quickly and efficiently encapsulates the toxins in chocolate — the encapsulated toxins safely pass through your dog's digestive system. The active ingredients specifically affect the toxins but remain unreactive to other molecules, so there are few, if any, side effects.”\n\nYour “Chocolate Rescue for Dogs” product is a “new animal drug” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, or 572 of the FD&C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. Your “Chocolate Rescue for Dogs” product is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listed by the FDA, and therefore is considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case 665098” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nCc: info@chocolaterescuefordogs.com","Essential Research, LLC","essential-research-llc-665098-08162023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fessential-research-llc-665098-08162023","2026-10-26T08:08:36.319506+00:00","2023-08-29","665098","Animal & Veterinary","Amadeus Benitez, CEO","2026-08-20T00:43:51.651+00:00","2023-08-16",{"id":96,"raw":97,"subject":12,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":26,"closeout_date":19,"issuing_office":101,"recipient_name":111,"body_fetched_at":112,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},6165,[98,99,100,101,12,13,13,13],"\u003Ctime datetime=\"2022-07-26T13:20:00Z\">07\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-08T04:00:00Z\">07\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcustom-research-labs-inc-616184-07082022\">Custom Research Labs Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Steven Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Custom Research Labs Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>432 W. Alondra Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gardena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90248-2425\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:steve@customresearchlabs.com\"> steve@customresearchlabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 8, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Kim:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Custom Research Labs Inc., FEI: 3008268262, at 432 W. Alondra Blvd., Gardena, from June 1 to June 4, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a), and are misbranded under sections 502(c) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(c) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 10, 2021, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test incoming active pharmaceutical ingredients (e.g., camphor and menthol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. For active pharmaceutical ingredients (API), you relied solely on certificates of analysis (COA) from suppliers where you have not established their reliability. In addition, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for purified water and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>For example,\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate API Testing\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm relied on the COA from unqualified suppliers of camphor and menthol. These components are used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. The FDA requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>In addition, you did not ensure all specifications of your components were in conformance with USP. For example, the COA specification for impurity testing for halogens of camphor gum USP states “CONFORMS TO USP.” However, the USP monograph for camphor gum has a quantitative acceptance criterion for halogens and the quantitative result was not provided. Also, you provided the COA for menthol USP, which lacked impurity testing data for limit of nonvolatile residue and related compounds as required per the USP monograph.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that both camphor and menthol have been validated by a third-party laboratory “through assay.” Your response is inadequate because you failed to demonstrate that all appropriate tests for camphor and menthol were performed or that appropriate validation of the supplier’s test results was conducted. Further, you did not address the discrepancies between your third-party laboratory’s COA and USP specifications.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Component Water\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP purified water monograph and appropriate microbial limits. Further, your firm lacked sufficient testing of your DI water system. Inadequate water system design is a repeat observation from your 2016 FDA inspection. For example,\u003C\u002Fp>\n\n\u003Cp>• Your firm has no record of testing water for Total Organic Carbon (TOC). In your response you stated, \"All products produced since March 2020, have passed micro testing ensuring there are no TOC issues.\" You committed to purchase a TOC meter but failed to provide a timeline for the purchase and validation of the equipment. Further, the vendor stated in the TOC meter proposal provided in your response that, based on the current design of the system, TOC will most likely not meet the specification and that a recirculation pump must be added to keep the TOC low. Your response lacked details on whether you will establish appropriate TOC specifications and ensure your water system is adequately designed to meet those specifications.\u003Cbr>\n• Since March 2020, your firm failed to monitor conductivity of your water used as a component in your drug products. You also failed to establish a specification for conductivity. Your response failed to address the lack of a conductivity specification.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your firm’s water system point-of-use ports yielded elevated bioburden counts of 1.3 x 10\u003Csup>6\u003C\u002Fsup> and 2.3 x 10\u003Csup>4\u003C\u002Fsup> total plate count (TPC)\u002Fml for water used as a component in your drug products. Your action limit was \u003Cstrong>(b)(4)\u003C\u002Fstrong> TPC\u002Fml. Your associated investigations did not adequately determine potential root cause(s) to fully investigate product impact. Your response did not address bioburden failures that lacked adequate investigation. Also, in multiple instances, the pH of your water system Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> was out of specification with results ranging between 3.59 and 4.73. Your pH specification was \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In your response, you stated that, batches manufactured during this period were reviewed and there was no evidence that batches were affected. However, you did not provide data to substantiate this claim.\u003C\u002Fp>\n\n\u003Cp>Without routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fp>\n\n\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>• A procedure for your water system monitoring that specifies routine chemical and microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your water system design and maintenance including the sanitization process. In addition, provide a summary of the qualification protocol(s) for your component water system. Also, include a summary of any improvements made to your system design and program for routine control and maintenance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to validate the manufacturing process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product currently in distribution. This is a repeat observation from your 2016 FDA inspection.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that the validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product was not completed yet because you “require \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches before we can validate a formula,” and only two batches have been completed. However, as observed during the inspection, there are at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches manufactured using an unvalidated process and currently in distribution. Your response is inadequate because you failed to conduct an assessment or identify corrective actions to address unvalidated drug products currently in distribution.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A timeline for performing appropriate process performance qualification for each of your marketed drug products, including how you will ensure proper validation prior to distribution of drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use&nbsp;results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked stability data to support the expiration dates for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product which is currently in distribution. This is a repeat observation from your 2016 FDA inspection. Instead, to support the two-year expiration date of your drug product, you provided data from a different formulation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;that failed its long-term stability study and was stopped at the three-month time point because of changes in viscosity. The long-term stability test report determined the need for reformulation.\u003C\u002Fp>\n\n\u003Cp>In your response, you explained that because a retain sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product passed microbiology and assay testing, the two-year expiration date was justified for the drug product. However, the retain sample tested was the formulation that failed its long-term stability study for viscosity. Further, you did not provide testing to ensure the retain sample met all specifications required during your stability studies such as odor, pH, and viscosity. Your response is inadequate because you failed to provide a report that ensures adequate stability studies have been conducted for all drug products.\u003C\u002Fp>\n\n\u003Cp>Without an adequate stability program, you cannot confirm that your drug products will meet established specifications and all pre-determined quality criteria throughout their shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; o Stability-indicating methods.\u003Cbr>\n&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>\n&nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to review batch records before releasing drug product for distribution. Your QU procedure specifies that the Quality Assurance designee is responsible for reviewing all manufacturing, production, and quality records. However, during the inspection, one of your QU employees stated that the shipping and production department had released drug product batches before the batch record had been reviewed by the QU. It was also stated that your firm is trying to catch up on back logged batch record reviews. During the inspection, we observed that drug product batch records were incomplete at the time of release for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that all pending batch record reviews have been completed and that you revised your record review procedure to include batch sheet approval and other controls. However, your response failed to provide details of the outcome of that review. Your response is inadequate because you failed to identify appropriate corrective actions when the QU released drug products before batch record completion to ensure that drug products met established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>Your response demonstrated a lack of CGMP understanding and the lack of adequate quality oversight and control from incoming products to finished product.\u003C\u002Fp>\n\n\u003Cp>Your inspectional history indicates that your quality unit is not fully exercising its authority and responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Unapproved New Drug Violations\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21, U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> are topical products intended for use as external analgesics. “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” are topical products intended for use as consumer topical antiseptics. Examples of claims from the products’ labeling, including websites listed on product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of these products include, but may not be limited to, the following: From your website \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>On your website homepage:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your website for “HOW IT WORKS”:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz)\u003Cbr>\n“Easy To Use Spray + Surface Disinfectant . . . \u003Cem>\u003Cstrong>Uses\u003C\u002Fstrong>\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> ● for handwashing to decrease microbial contamination on the skin ● may be reapplied during the day as required ● for disinfecting surfaces” [from your product label]\u003C\u002Fp>\n\n\u003Cp>“BAK-OFF Instant Hand Sanitizer”\u003Cbr>\n“Lavender Oil . . . Rosemary Leaf Oil . . . Geranium Flower Oil . . . Antimicrobial Properties . . . \u003Cem>\u003Cstrong>Uses\u003C\u002Fstrong>\u003C\u002Fem> To decrease bacteria on the skin ▪ Recommended for repeated use” [from your product label]\u003Cbr>\n“\u003Cstrong>Made in California\u003C\u002Fstrong> \u003Cem>from\u003C\u002Fem> Ethically Sourced Cosmetic Grade Ingredients with Antimicrobial Properties : . . . ● Aloe Vera . . . ● Lavender Oil . . . ● Rosemary Leaf Oil . . . ● Geranium Flower Oil . . . ●Specially Denatured Alcohol 70% vv” ” (from \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fp>\n\n\u003Cp>As described below, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>External Analgesic Drug Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are topical external analgesic drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order. However, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” do not conform to the conditions of use specified in the final administrative order for the reasons described below.\u003C\u002Fp>\n\n\u003Cp>The active ingredients, in your products, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are not active ingredients included in the final administrative order for topical external analgesics. Although the product labeling does not specifically list these ingredients as active ingredients, the website claims for these ingredients, such as “With \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> temporarily reduces inflammation and pain,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Used in homeopathic medicine as a treatment for bruises, sprains, pains, and other wounds,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Alternative pain relief method applied to the skin for relief from sore muscles, aching joints, pain or inflammation” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Natural pain reliever that can stimulate circulation to promote healing,” demonstrate that these are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because each ingredient is intended to furnish pharmacological activity.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Furthermore, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products fall under section 505G(a)(5) of the FD&amp;C Act (21 USC 355h(a)(5)), because the FDA has determined that counterirritant external analgesic drug products with the active ingredient eucalyptus oil are not GRASE under a final determination issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, these products are new drugs under FD&amp;C Act 201(p).\u003C\u002Fp>\n\n\u003Cp>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” is labeled for use as a counterirritant drug product because it includes claims associated with muscular aches and pains. The labeled active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, falls below the allowable dosage range of 3% -11% for this active ingredient when used as a counterirritant in the 1983 TFM (48 FR 5862 at 5868).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Further, the product labeling for “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” includes the claim of fibromyalgia pain as an indication, which is not an indication that is permitted consistent with the conditions of marketing under the topical external analgesic final administrative order. This labeled intended use goes beyond merely describing the general intended use for external analgesic products as set forth in the final administrative order.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Topical Antiseptic Drug Products\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” are topical products intended for use as topical antiseptic drug products. As described below, these topical antiseptic drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic -Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule and the 2013 Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule or final rule. Thus, neither “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) nor “BAK-OFF Instant Hand Sanitizer” meets the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>As previously noted, statements on the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) label suggest both that the product is a consumer antiseptic wash and a consumer antiseptic rub. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in a consumer antiseptic hand wash under the 2013 Consumer Antiseptic Washes Proposed Rule as further amended in the 2016 Final Rule.\u003C\u002Fp>\n\n\u003Cp>In addition, Lavender Oil, Rosemary Leaf Oil, and Geranium Flower Oil are clearly represented as active ingredients in the labeling of your “BAK-OFF Instant Hand Sanitizer” drug product.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Specifically, your product labeling for “BAK-OFF Instant Hand Sanitizer” features on the Principal Display Panel (PDP) “Lavender Oil . . . Rosemary Leaf Oil . . . Geranium Flower Oil . . . Antimicrobial Properties.” Your labeling further emphasizes these ingredients are intended to have a therapeutic effect with the statements “Our Hand Sanitizer with Antimicrobial Properties is carefully formulated with natural and botanical non-toxic ingredients that moisturize and are gentle for the skin, but 99% effective against germs.” As noted above, Lavender Oil, Rosemary Leaf Oil, and Geranium Flower Oil are not active ingredients in any applicable final monograph or TFM for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&amp;C Act. Therefore, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” do not conform with the TFM, or the applicable requirements.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz) is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C 352(c), because the product’s Drug Facts panel contains extraneous information that goes beyond the required directions described in the rulemakings mentioned above. Specifically, 21 CFR 201.66(d)(7) states that additional information not described in the content requirements for OTC drug products should not appear in the Drug Facts panel. However, the Uses section for your product’s Drug Facts panel includes language such as “for disinfecting surfaces” that is not consistent with the uses provided for in the applicable rulemakings for consumer antiseptic rubs and consumer antiseptic washes.\u003C\u002Fp>\n\n\u003Cp>Further, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are misbranded under section 502(ee) of the FD&amp;C Act, 21U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section, and are not the subjects of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that you manufacture several OTC drug products, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” that are labeled with a Drug Facts panel in which the purpose identifies these products as a “Pain Reliever.” While we acknowledge that neither product currently appears to be available for purchase or distribution in the US, we want to advise you of their regulatory status under 505G of the FD&amp;C Act, 21 U.S.C. 355G. “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are considered to be drugs as defined under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended for use as external analgesics. Section 505G of the FD&amp;C Act, 21 U.S.C. 355h governs nonprescription drugs marketed without an approved application. These products prominently feature cannabidiol (CBD) on the principal display panel and include statements such as, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> CBD.” Although CBD is labeled as an inactive ingredient in the labels of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” the labeling for these products clearly represents CBD as an active ingredient.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Currently, a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not generally recognized as safe and effective and are new drugs which require an approved application to be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements for nonprescription drug products under section 505G of the FD&amp;C Act. In particular, such product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR 330.1(e)\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Additionally, an inactive ingredient should not exert pharmacological effect\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>We note that CBD also cannot legally be sold in a conventional food or dietary supplement product. Please see the following for more information: \u003Cem>FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) and Warning Letters and Test Results for Cannabidiol-Related Products\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with the unique identifier: \u003Cstrong>CMS# 616184\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to ORAPHARM4_Responses@FDA.HHS.GOV with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact LCDR Rumany Penn, Compliance Officer, at (949) 608-4409, or by email at Rumany.Penn@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lance M. De Souza\u003Cbr>\nActing Director, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>David V. Ward\u003Cbr>\nPresident\u003Cbr>\nCustom Research Labs Inc.\u003Cbr>\n432 W. Alondra Blvd.\u003Cbr>\nGardena, CA 90248-2425\u003Cbr>\ndavid@customresearchlabs.com\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> We note that your “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER” labeling contains conflicting information about whether it should be used as a consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs and the Drug Facts labeling of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “wet hands thoroughly with product” followed by the statement “briskly rub hands together until dry.” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> HAND SANITIZER,” however, does not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash as discussed in this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> On November 7, 1990, FDA issued a final rule establishing that OTC counterirritant external analgesic drug products containing certain active ingredients, including eucalyptus oil, are not generally recognized as safe and effective. 55 FR 46920. FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(10)(ii). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at \u003Cem>OTC Monographs@FDA\u003C\u002Fem>, \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> As noted earlier, the 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order under 505G(b)(8) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). CBD was not included as an active ingredient under this TFM. Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see 21 CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 330.1(e)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Steven Kim\n\nRecipient Title\n\nChief Executive Officer\n\nCustom Research Labs Inc.\n\n432 W. Alondra Blvd.\n\nGardena, CA 90248-2425\n\nUnited States\n\nsteve@customresearchlabs.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nJuly 8, 2022\n\nDear Mr. Kim:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Custom Research Labs Inc., FEI: 3008268262, at 432 W. Alondra Blvd., Gardena, from June 1 to June 4, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, “(b)(4),” “(b)(4) HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a), and are misbranded under sections 502(c) and (ee) of the FD&C Act, 21 U.S.C. 352(c) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe reviewed your June 10, 2021, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to test incoming active pharmaceutical ingredients (e.g., camphor and menthol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. For active pharmaceutical ingredients (API), you relied solely on certificates of analysis (COA) from suppliers where you have not established their reliability. In addition, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for purified water and appropriate microbial limits.\n\nFor example,\n\nInadequate API Testing\n\nYour firm relied on the COA from unqualified suppliers of camphor and menthol. These components are used in the manufacture of your (b)(4) drug product. The FDA requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals.\n\nIn addition, you did not ensure all specifications of your components were in conformance with USP. For example, the COA specification for impurity testing for halogens of camphor gum USP states “CONFORMS TO USP.” However, the USP monograph for camphor gum has a quantitative acceptance criterion for halogens and the quantitative result was not provided. Also, you provided the COA for menthol USP, which lacked impurity testing data for limit of nonvolatile residue and related compounds as required per the USP monograph.\n\nIn your response, you stated that both camphor and menthol have been validated by a third-party laboratory “through assay.” Your response is inadequate because you failed to demonstrate that all appropriate tests for camphor and menthol were performed or that appropriate validation of the supplier’s test results was conducted. Further, you did not address the discrepancies between your third-party laboratory’s COA and USP specifications.\n\nInadequate Component Water\n\nYour firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP purified water monograph and appropriate microbial limits. Further, your firm lacked sufficient testing of your DI water system. Inadequate water system design is a repeat observation from your 2016 FDA inspection. For example,\n\n• Your firm has no record of testing water for Total Organic Carbon (TOC). In your response you stated, \"All products produced since March 2020, have passed micro testing ensuring there are no TOC issues.\" You committed to purchase a TOC meter but failed to provide a timeline for the purchase and validation of the equipment. Further, the vendor stated in the TOC meter proposal provided in your response that, based on the current design of the system, TOC will most likely not meet the specification and that a recirculation pump must be added to keep the TOC low. Your response lacked details on whether you will establish appropriate TOC specifications and ensure your water system is adequately designed to meet those specifications.\n\n• Since March 2020, your firm failed to monitor conductivity of your water used as a component in your drug products. You also failed to establish a specification for conductivity. Your response failed to address the lack of a conductivity specification.\n\nFurthermore, your firm’s water system point-of-use ports yielded elevated bioburden counts of 1.3 x 106 and 2.3 x 104 total plate count (TPC)\u002Fml for water used as a component in your drug products. Your action limit was (b)(4) TPC\u002Fml. Your associated investigations did not adequately determine potential root cause(s) to fully investigate product impact. Your response did not address bioburden failures that lacked adequate investigation. Also, in multiple instances, the pH of your water system Line (b)(4) was out of specification with results ranging between 3.59 and 4.73. Your pH specification was (b)(4). In your response, you stated that, batches manufactured during this period were reviewed and there was no evidence that batches were affected. However, you did not provide data to substantiate this claim.\n\nWithout routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• A procedure for your water system monitoring that specifies routine chemical and microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\n• A comprehensive, independent assessment of your water system design and maintenance including the sanitization process. In addition, provide a summary of the qualification protocol(s) for your component water system. Also, include a summary of any improvements made to your system design and program for routine control and maintenance.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to validate the manufacturing process for (b)(4) drug product currently in distribution. This is a repeat observation from your 2016 FDA inspection.\n\nIn your response, you stated that the validation of your (b)(4) drug product was not completed yet because you “require (b)(4) batches before we can validate a formula,” and only two batches have been completed. However, as observed during the inspection, there are at least (b)(4) batches manufactured using an unvalidated process and currently in distribution. Your response is inadequate because you failed to conduct an assessment or identify corrective actions to address unvalidated drug products currently in distribution.\n\nIn response to this letter, provide:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification for each of your marketed drug products, including how you will ensure proper validation prior to distribution of drugs.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm lacked stability data to support the expiration dates for your (b)(4) drug product which is currently in distribution. This is a repeat observation from your 2016 FDA inspection. Instead, to support the two-year expiration date of your drug product, you provided data from a different formulation of (b)(4) that failed its long-term stability study and was stopped at the three-month time point because of changes in viscosity. The long-term stability test report determined the need for reformulation.\n\nIn your response, you explained that because a retain sample of (b)(4) drug product passed microbiology and assay testing, the two-year expiration date was justified for the drug product. However, the retain sample tested was the formulation that failed its long-term stability study for viscosity. Further, you did not provide testing to ensure the retain sample met all specifications required during your stability studies such as odor, pH, and viscosity. Your response is inadequate because you failed to provide a report that ensures adequate stability studies have been conducted for all drug products.\n\nWithout an adequate stability program, you cannot confirm that your drug products will meet established specifications and all pre-determined quality criteria throughout their shelf life.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no Stability-indicating methods.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\n• All procedures that describe these and other elements of your remediated stability program.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) failed to review batch records before releasing drug product for distribution. Your QU procedure specifies that the Quality Assurance designee is responsible for reviewing all manufacturing, production, and quality records. However, during the inspection, one of your QU employees stated that the shipping and production department had released drug product batches before the batch record had been reviewed by the QU. It was also stated that your firm is trying to catch up on back logged batch record reviews. During the inspection, we observed that drug product batch records were incomplete at the time of release for (b)(4) Lot (b)(4), and (b)(4) and for (b)(4) Lot (b)(4).\n\nIn your response, you stated that all pending batch record reviews have been completed and that you revised your record review procedure to include batch sheet approval and other controls. However, your response failed to provide details of the outcome of that review. Your response is inadequate because you failed to identify appropriate corrective actions when the QU released drug products before batch record completion to ensure that drug products met established specifications for identity, strength, quality, and purity.\n\nYour response demonstrated a lack of CGMP understanding and the lack of adequate quality oversight and control from incoming products to finished product.\n\nYour inspectional history indicates that your quality unit is not fully exercising its authority and responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nUnapproved New Drug and Misbranding Violations\n\nUnapproved New Drug Violations\n\n“(b)(4) HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21, U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, “(b)(4),” and “(b)(4) are topical products intended for use as external analgesics. “(b)(4) HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” are topical products intended for use as consumer topical antiseptics. Examples of claims from the products’ labeling, including websites listed on product labels, that provide evidence of the intended uses (as defined by 21 CFR 201.128) of these products include, but may not be limited to, the following: From your website (b)(4):\n\nOn your website homepage:\n\n(b)(4)\n\nOn your website for “HOW IT WORKS”:\n\n(b)(4)\n\n“(b)(4) HAND SANITIZER” (8 oz and 16 oz)\n\n“Easy To Use Spray + Surface Disinfectant . . . Uses1 ● for handwashing to decrease microbial contamination on the skin ● may be reapplied during the day as required ● for disinfecting surfaces” [from your product label]\n\n“BAK-OFF Instant Hand Sanitizer”\n\n“Lavender Oil . . . Rosemary Leaf Oil . . . Geranium Flower Oil . . . Antimicrobial Properties . . . Uses To decrease bacteria on the skin ▪ Recommended for repeated use” [from your product label]\n\n“Made in California from Ethically Sourced Cosmetic Grade Ingredients with Antimicrobial Properties : . . . ● Aloe Vera . . . ● Lavender Oil . . . ● Rosemary Leaf Oil . . . ● Geranium Flower Oil . . . ●Specially Denatured Alcohol 70% vv” ” (from (b)(4))\n\nAs described below, “(b)(4) HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “(b)(4) HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nExternal Analgesic Drug Products\n\n“(b)(4)” and “(b)(4)” are topical external analgesic drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be GRASE and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order. However, “(b)(4),” and “(b)(4)” do not conform to the conditions of use specified in the final administrative order for the reasons described below.\n\nThe active ingredients, in your products, “(b)(4)” and “(b)(4),” i.e., (b)(4), and (b)(4), are not active ingredients included in the final administrative order for topical external analgesics. Although the product labeling does not specifically list these ingredients as active ingredients, the website claims for these ingredients, such as “With (b)(4), and (b)(4) temporarily reduces inflammation and pain,” “(b)(4) Used in homeopathic medicine as a treatment for bruises, sprains, pains, and other wounds,” “(b)(4) Alternative pain relief method applied to the skin for relief from sore muscles, aching joints, pain or inflammation” and “(b)(4) Natural pain reliever that can stimulate circulation to promote healing,” demonstrate that these are each an “active ingredient” as defined in 21 CFR 201.66(b)(2) because each ingredient is intended to furnish pharmacological activity.2\n\nFurthermore, your “(b)(4)” and “(b)(4)” products fall under section 505G(a)(5) of the FD&C Act (21 USC 355h(a)(5)), because the FDA has determined that counterirritant external analgesic drug products with the active ingredient eucalyptus oil are not GRASE under a final determination issued under 21 CFR part 330.3 Therefore, these products are new drugs under FD&C Act 201(p).\n\nYour “(b)(4)” is labeled for use as a counterirritant drug product because it includes claims associated with muscular aches and pains. The labeled active ingredient, (b)(4), falls below the allowable dosage range of 3% -11% for this active ingredient when used as a counterirritant in the 1983 TFM (48 FR 5862 at 5868).4 Further, the product labeling for “(b)(4)” includes the claim of fibromyalgia pain as an indication, which is not an indication that is permitted consistent with the conditions of marketing under the topical external analgesic final administrative order. This labeled intended use goes beyond merely describing the general intended use for external analgesic products as set forth in the final administrative order.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “(b)(4),” and “(b)(4)” drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nTopical Antiseptic Drug Products\n\nBased on the above labeling claims, “(b)(4) HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” are topical products intended for use as topical antiseptic drug products. As described below, these topical antiseptic drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic -Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use in a consumer antiseptic rub. Additionally, OTC consumer antiseptic washes were addressed in “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) (Consumer Antiseptic Washes Proposed Rule) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016). We note that ethyl alcohol is not one of the active ingredients that was classified as Category III for use as an active ingredient in a consumer antiseptic wash. Under the Consumer Antiseptic Washes rulemaking, ethyl alcohol was determined to be ineligible for evaluation under the OTC Drug Review for use as an active ingredient in consumer antiseptic washes.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, “(b)(4) HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule and the 2013 Consumer Antiseptic Washes Proposed Rule, nor any other TFM, proposed rule or final rule. Thus, neither “(b)(4) HAND SANITIZER” (8 oz and 16 oz) nor “BAK-OFF Instant Hand Sanitizer” meets the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAs previously noted, statements on the “(b)(4) HAND SANITIZER” (8 oz and 16 oz) label suggest both that the product is a consumer antiseptic wash and a consumer antiseptic rub. However, ethyl alcohol (in any concentration) is not an active ingredient permitted for use in a consumer antiseptic hand wash under the 2013 Consumer Antiseptic Washes Proposed Rule as further amended in the 2016 Final Rule.\n\nIn addition, Lavender Oil, Rosemary Leaf Oil, and Geranium Flower Oil are clearly represented as active ingredients in the labeling of your “BAK-OFF Instant Hand Sanitizer” drug product.5 Specifically, your product labeling for “BAK-OFF Instant Hand Sanitizer” features on the Principal Display Panel (PDP) “Lavender Oil . . . Rosemary Leaf Oil . . . Geranium Flower Oil . . . Antimicrobial Properties.” Your labeling further emphasizes these ingredients are intended to have a therapeutic effect with the statements “Our Hand Sanitizer with Antimicrobial Properties is carefully formulated with natural and botanical non-toxic ingredients that moisturize and are gentle for the skin, but 99% effective against germs.” As noted above, Lavender Oil, Rosemary Leaf Oil, and Geranium Flower Oil are not active ingredients in any applicable final monograph or TFM for purposes of establishing eligibility for lawful marketing without an approved application under section 505G of the FD&C Act. Therefore, “(b)(4) HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” do not conform with the TFM, or the applicable requirements.\n\nWe are not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “(b)(4) HAND SANITIZER” (8 oz and 16 oz) and “BAK-OFF Instant Hand Sanitizer” drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\n\nMisbranded Drug Violations\n\nIn addition, “(b)(4) HAND SANITIZER” (8 oz and 16 oz) is misbranded under section 502(c) of the FD&C Act, 21 U.S.C 352(c), because the product’s Drug Facts panel contains extraneous information that goes beyond the required directions described in the rulemakings mentioned above. Specifically, 21 CFR 201.66(d)(7) states that additional information not described in the content requirements for OTC drug products should not appear in the Drug Facts panel. However, the Uses section for your product’s Drug Facts panel includes language such as “for disinfecting surfaces” that is not consistent with the uses provided for in the applicable rulemakings for consumer antiseptic rubs and consumer antiseptic washes.\n\nFurther, “(b)(4) HAND SANITIZER” (8 oz and 16 oz), and “BAK-OFF Instant Hand Sanitizer” are misbranded under section 502(ee) of the FD&C Act, 21U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section, and are not the subjects of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdditionally, we note that you manufacture several OTC drug products, “(b)(4)” and “(b)(4)” that are labeled with a Drug Facts panel in which the purpose identifies these products as a “Pain Reliever.” While we acknowledge that neither product currently appears to be available for purchase or distribution in the US, we want to advise you of their regulatory status under 505G of the FD&C Act, 21 U.S.C. 355G. “(b)(4)” and “(b)(4)” are considered to be drugs as defined under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended for use as external analgesics. Section 505G of the FD&C Act, 21 U.S.C. 355h governs nonprescription drugs marketed without an approved application. These products prominently feature cannabidiol (CBD) on the principal display panel and include statements such as, “(b)(4) CBD.” Although CBD is labeled as an inactive ingredient in the labels of “(b)(4)” and “(b)(4),” the labeling for these products clearly represents CBD as an active ingredient.6 Currently, a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not generally recognized as safe and effective and are new drugs which require an approved application to be legally marketed.\n\nFurthermore, even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements for nonprescription drug products under section 505G of the FD&C Act. In particular, such product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR 330.1(e)7. Additionally, an inactive ingredient should not exert pharmacological effect8 and must be safe when used at the intended dosage.9\n\nWe note that CBD also cannot legally be sold in a conventional food or dietary supplement product. Please see the following for more information: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) and Warning Letters and Test Results for Cannabidiol-Related Products.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with the unique identifier: CMS# 616184\n\nSend your electronic response to ORAPHARM4_Responses@FDA.HHS.GOV with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nIf you have questions regarding this letter, please contact LCDR Rumany Penn, Compliance Officer, at (949) 608-4409, or by email at Rumany.Penn@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLance M. De Souza\n\nActing Director, Division of Pharmaceutical Quality Operations IV\n\nCc:\n\nDavid V. Ward\n\nPresident\n\nCustom Research Labs Inc.\n\n432 W. Alondra Blvd.\n\nGardena, CA 90248-2425\n\ndavid@customresearchlabs.com\n\n________________________\n\n1 We note that your “(b)(4) HAND SANITIZER” labeling contains conflicting information about whether it should be used as a consumer antiseptic rub\u002Fconsumer antiseptic wash or consumer antiseptic rub. The term “hand sanitizer” generally refers to consumer antiseptic rubs and the Drug Facts labeling of your product both indicates that the product is to be used for handwashing (presumably with water) and suggests that it should be used without water (i.e., “wet hands thoroughly with product” followed by the statement “briskly rub hands together until dry.” “(b)(4) HAND SANITIZER,” however, does not conform to the requirements for either a consumer antiseptic rub or a consumer antiseptic wash as discussed in this letter.\n\n2 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n3 On November 7, 1990, FDA issued a final rule establishing that OTC counterirritant external analgesic drug products containing certain active ingredients, including eucalyptus oil, are not generally recognized as safe and effective. 55 FR 46920. FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(10)(ii). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\n\n4 As noted earlier, the 1983 external analgesic TFM, in combination with subsequent determinations, was deemed to be a final administrative order under 505G(b)(8) of the FD&C Act.\n\n5 Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n6 See Tentative Final Monograph (TFM) for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983). CBD was not included as an active ingredient under this TFM. Under 21 CFR 201.66(b), an active ingredient is a component of a drug intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\n7 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\n\n8 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see 21 CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n9 See 21 CFR 330.1(e)","Custom Research Labs Inc.","custom-research-labs-inc-616184-07082022","2026-08-19T04:06:54.551565+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcustom-research-labs-inc-616184-07082022","2026-10-26T08:08:20.064667+00:00","2022-07-26","616184","Mr. Steven Kim","2026-08-20T01:43:51.282+00:00","2022-07-08",{"id":115,"raw":116,"subject":39,"body_html":118,"body_text":119,"firm_name":120,"letter_id":121,"created_at":44,"fei_number":19,"letter_url":122,"updated_at":123,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":124,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":125,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1133,[35,36,117,11,38,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsummit-research-peptides-695607-12102024\">Summit Research Peptides\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Summit Research Peptides\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1678 Montgomery Hwy, Ste 104-285\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hoover\u003C\u002Fspan>, \u003Cspan>AL\u003C\u002Fspan> \u003Cspan>35216\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@summitpeptides.shop\"> support@summitpeptides.shop\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@summitpeptides.shop\"> info@summitpeptides.shop\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 10, 2024\u003C\u002Fp>\u003Cp>RE: 695607\u003C\u002Fp>\u003Cp>Dear Summit Research Peptides:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsummitpeptides.shop in October 2024 and has observed that your website offers “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products for sale in the United States. We have also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002Fsummitpeptides\u002F. Your social media website directs consumers to your https:\u002F\u002Fsummitpeptides.shop website to purchase your products. As described below, your “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products as “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY,” evidence obtained from your websites establish that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act 21, U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>From your “Semagultide” (or “Sema”) product webpage https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Fsema-10-pack?variant=45101962887394:\u003Cbr>• “Overview: Sema is a GLP-1 analog with therapeutic applications in type 2 diabetes and obesity. It enhances insulin secretion and reduces appetite, leading to improved glycemic control and weight loss.”\u003Cbr>• “Product Features:\u003Cbr>&nbsp; o GLP-1 analog simulating human incretin activity\u003Cbr>&nbsp; o Enhances insulin secretion and beta cell function\u003Cbr>&nbsp; o Delays gastric emptying, reducing appetite\u003Cbr>&nbsp; o Supports weight management in obesity\u003Cbr>&nbsp; o Exhibits cardioprotective and neuroprotective potential”\u003C\u002Fp>\u003Cp>From your “Retatrutide” (or “Reta”) product website https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Freta?variant=45843937525986:\u003Cbr>• “Overview: Reta is an experimental tritagonist drug targeting three hormone receptors: GLP-1, GIP, and glucagon. It is designed to mimic these hormones' effects, such as enhancing satiety, regulating blood sugar, and suppressing appetite.”\u003Cbr>• “Product Features:\u003Cbr>&nbsp; o Tritagonist: Interacts with GLP-1, GIP, and glucagon receptors.\u003Cbr>&nbsp; o Regulates appetite and blood sugar levels.\u003Cbr>&nbsp; o Administered via specific receptors in the brain and gut.”\u003Cbr>• “Conclusion: Reta presents a promising approach for obesity and diabetes treatment, offering a novel mechanism of action through a triple-receptor agonist profile. It’s a significant development in the search for more effective treatments for these conditions.”\u003C\u002Fp>\u003Cp>On your social media website at https:\u002F\u002Fwww.facebook.com\u002Fsummitpeptides\u002F:\u003Cbr>• May 18, 2024 post: “Unlock Maximum Health Benefits with Cagrilintide and Semaglutide . . . designed to help you achieve your health goals more effectively than ever before! Enhanced Weight Loss: Achieve superior weight reduction with the synergistic effects of Cagrilintide and Semaglutide. Experience greater weight loss results and take control of your journey to a healthier you. Optimized Cardiovascular Health: Support your heart health with this powerful combination. Promote better cardiovascular health and ensure your heart remains strong and healthy. Improved Glucose Management: Maintain stable blood sugar levels and achieve effective glucose control with the combined benefits of Cagrilintide and Semaglutide, enhancing your overall metabolic health . . . Achieve Your Weight Loss Goals Faster with Cagrilintide &amp; Semaglutide”\u003C\u002Fp>\u003Cp>From your “Tirzepatide” (or “Tirz”) product website https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Ftirz?_pos=1&amp;_sid=39f4021bd&amp;_ss=r\u003Cbr>• “Overview: Tirzepatide is a cutting-edge synthetic derivative of the Glucagon-Like Peptide-1 (GLP-1), designed specifically for the scientific community to advance research in metabolic disorders and diabetes management. With its unique structure and mode of action, Tirz represents a promising frontier for investigating new therapeutic strategies.”\u003Cbr>• “Research Applications: Tirz is extensively utilized in preclinical studies to explore its potential in:\u003Cbr>&nbsp; o Enhancing insulin secretion\u003Cbr>&nbsp; o Regulating blood sugar levels\u003Cbr>&nbsp; o Investigating weight management pathways\u003Cbr>&nbsp; o Exploring cardiovascular benefits.”\u003C\u002Fp>\u003Cp>From your “Mazdutide” product website https:\u002F\u002Fsummitpeptides.shop\u002Fcollections\u002Ffull-catalog\u002Fproducts\u002Fmazdutide\u003Cbr>• “Mazdutide is an investigational peptide with a novel dual-action mechanism, designed to mimic and enhance the biological activities of certain endogenous hormones. It is at the forefront of research in metabolic disorders and has shown promising results in early studies related to weight management and glucose regulation.”\u003Cbr>• “Mazdutide is primarily investigated for its potential in:\u003Cbr>&nbsp; o Understanding and enhancing wight loss mechanisms\u003Cbr>&nbsp; o Improving glucose homeostasis in diabetic models\u003Cbr>&nbsp; o Studying hormone receptor interactions and signaling pathways\u003Cbr>&nbsp; o Exploring its effects on metabolic rate and energy expenditure\u003C\u002Fp>\u003Cp>Your “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nSummit Research Peptides\n\n1678 Montgomery Hwy, Ste 104-285\n\nHoover, AL 35216\n\nUnited States\n\nsupport@summitpeptides.shop\n\ninfo@summitpeptides.shop\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 10, 2024\nRE: 695607\nDear Summit Research Peptides:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fsummitpeptides.shop in October 2024 and has observed that your website offers “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products for sale in the United States. We have also reviewed your social media website at https:\u002F\u002Fwww.facebook.com\u002Fsummitpeptides\u002F. Your social media website directs consumers to your https:\u002F\u002Fsummitpeptides.shop website to purchase your products. As described below, your “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nDespite statements on your product labeling marketing your products as “RESEARCH USE ONLY” and “INTENDED AS A RESEARCH CHEMICAL ONLY,” evidence obtained from your websites establish that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:\nFrom your “Semagultide” (or “Sema”) product webpage https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Fsema-10-pack?variant=45101962887394:\n• “Overview: Sema is a GLP-1 analog with therapeutic applications in type 2 diabetes and obesity. It enhances insulin secretion and reduces appetite, leading to improved glycemic control and weight loss.”\n• “Product Features:\no GLP-1 analog simulating human incretin activity\no Enhances insulin secretion and beta cell function\no Delays gastric emptying, reducing appetite\no Supports weight management in obesity\no Exhibits cardioprotective and neuroprotective potential”\nFrom your “Retatrutide” (or “Reta”) product website https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Freta?variant=45843937525986:\n• “Overview: Reta is an experimental tritagonist drug targeting three hormone receptors: GLP-1, GIP, and glucagon. It is designed to mimic these hormones' effects, such as enhancing satiety, regulating blood sugar, and suppressing appetite.”\n• “Product Features:\no Tritagonist: Interacts with GLP-1, GIP, and glucagon receptors.\no Regulates appetite and blood sugar levels.\no Administered via specific receptors in the brain and gut.”\n• “Conclusion: Reta presents a promising approach for obesity and diabetes treatment, offering a novel mechanism of action through a triple-receptor agonist profile. It’s a significant development in the search for more effective treatments for these conditions.”\nOn your social media website at https:\u002F\u002Fwww.facebook.com\u002Fsummitpeptides\u002F:\n• May 18, 2024 post: “Unlock Maximum Health Benefits with Cagrilintide and Semaglutide . . . designed to help you achieve your health goals more effectively than ever before! Enhanced Weight Loss: Achieve superior weight reduction with the synergistic effects of Cagrilintide and Semaglutide. Experience greater weight loss results and take control of your journey to a healthier you. Optimized Cardiovascular Health: Support your heart health with this powerful combination. Promote better cardiovascular health and ensure your heart remains strong and healthy. Improved Glucose Management: Maintain stable blood sugar levels and achieve effective glucose control with the combined benefits of Cagrilintide and Semaglutide, enhancing your overall metabolic health . . . Achieve Your Weight Loss Goals Faster with Cagrilintide & Semaglutide”\nFrom your “Tirzepatide” (or “Tirz”) product website https:\u002F\u002Fsummitpeptides.shop\u002Fproducts\u002Ftirz?_pos=1&_sid=39f4021bd&_ss=r\n• “Overview: Tirzepatide is a cutting-edge synthetic derivative of the Glucagon-Like Peptide-1 (GLP-1), designed specifically for the scientific community to advance research in metabolic disorders and diabetes management. With its unique structure and mode of action, Tirz represents a promising frontier for investigating new therapeutic strategies.”\n• “Research Applications: Tirz is extensively utilized in preclinical studies to explore its potential in:\no Enhancing insulin secretion\no Regulating blood sugar levels\no Investigating weight management pathways\no Exploring cardiovascular benefits.”\nFrom your “Mazdutide” product website https:\u002F\u002Fsummitpeptides.shop\u002Fcollections\u002Ffull-catalog\u002Fproducts\u002Fmazdutide\n• “Mazdutide is an investigational peptide with a novel dual-action mechanism, designed to mimic and enhance the biological activities of certain endogenous hormones. It is at the forefront of research in metabolic disorders and has shown promising results in early studies related to weight management and glucose regulation.”\n• “Mazdutide is primarily investigated for its potential in:\no Understanding and enhancing wight loss mechanisms\no Improving glucose homeostasis in diabetic models\no Studying hormone receptor interactions and signaling pathways\no Exploring its effects on metabolic rate and energy expenditure\nYour “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” “Tirzepatide” (or “Tirz”), and “Mazdutide” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Summit Research Peptides","summit-research-peptides-695607-12102024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsummit-research-peptides-695607-12102024","2026-10-26T08:10:07.032747+00:00","695607","2026-08-19T17:08:09.798+00:00",{"id":127,"raw":128,"subject":135,"body_html":136,"body_text":137,"firm_name":138,"letter_id":139,"created_at":140,"fei_number":19,"letter_url":141,"updated_at":142,"action_type":22,"case_status":143,"posted_date":144,"marcs_cms_no":145,"product_type":26,"closeout_date":146,"issuing_office":132,"recipient_name":147,"body_fetched_at":148,"delivery_method":149,"recipient_title":19,"reference_number":19,"action_taken_date":150,"medical_device_id":19,"response_letter_date":19},3078,[129,130,131,132,133,13,134,13],"\u003Ctime datetime=\"2021-10-19T13:20:00Z\">10\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-30T04:00:00Z\">09\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-09302021\">Marcus Research Laboratory, Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-10022024\">\u003Ctime datetime=\"2024-10-04T04:00:00Z\">10\u002F04\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard A. Gilbert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marcus Research Laboratory, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1820 Delmar Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 30, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #615153\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Gilbert:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marcus Research Laboratory, Inc., FEI 1950348, at 1820 Delmar Blvd., Saint Louis, Missouri 63103, from May 3, to May 14, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your June 4, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to have the procedures and processes necessary to ensure the API manufactured at your facility meet established specifications for quality and purity.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures povidone iodine (PVP-I), API which may be used by your customers to produce presurgical preparatory products. During the inspection, we observed that your Quality Unit (QU) released API lots 100017872R and 100017911C without adequate procedures and processes to ensure that critical deviations are investigated and resolved.\u003C\u002Fp>\n\n\u003Cp>During the production of PVP-I lot 100017872R, on March 4, 2020, your production personnel observed PVP-I in reactor cabinet \u003Cstrong>(b)(4)\u003C\u002Fstrong> was smoldering. In response to the risk of imminent fire, production personnel used a fire extinguisher. Due to this incident, production did not proceed as normal. Associated drugs experienced inconsistent temperature exposure and additional processing and hold times. Your firm only tested the affected drums of material for percent of available iodine and released them for further processing.\u003C\u002Fp>\n\n\u003Cp>Similarly, on August 18, 2020 during the production of PVP-I lot 100017911C, your production personnel noted reactor cabinet \u003Cstrong>(b)(4)\u003C\u002Fstrong> was smoking. Production was ceased, and the material was held in unknown conditions. Your firm again, solely tested the affected drums of material for percent available iodine and released them for further processing.\u003C\u002Fp>\n\n\u003Cp>In both instances, your firm created deviation reports but released drugs based solely on composite results of percent available iodine. Your drugs were exposed to excess heat, fire, smoke, and debris. Additional contaminants or other particulates from the use of the fire extinguisher may have also compromised the material. In addition, the associated drugs experienced processing parameters beyond the normal validated state.\u003C\u002Fp>\n\n\u003Cp>Your firm did not perform additional testing on lots 100017872R and 100017911C to confirm that the API was not contaminated with harmful particulate matter or other contamination. Additionally, your firm lacked a risk or impact assessment to evaluate the exposure of the API to the extraneous debris or contamination resulting from the incidents. The QU released lots 100017872R and 100017911C without ensuring the critical deviation was fully resolved, and any residual chemical contaminants and particulate risks were fully addressed.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you are “currently seeking advice from a consultant to determine the best path forward on addressing this matter.” Your response is inadequate. You did not provide any supporting documentation that evaluated the impacted lots that you released. Specifically, you did not provide supporting documentation that would ensure the material was free of potentially harmful particulate matter and other extraneous contamination given the intended use of the API, including the potential for use in sterile drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>o A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fp>\n\n\u003Cp>o Provide concurrent stability data for the affected lots 100017872R and 100017911C.\u003C\u002Fp>\n\n\u003Cp>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fp>\n\n\u003Cp>o A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fp>\n\n\u003Cp>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>o Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• Your action plan to address any product quality or patient safety risks for batches of povidone iodine in U.S. distribution, including potential customer notifications and recalls or market withdrawals.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your equipment construction was inadequate because your product contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. During the inspection, we observed that critical povidone iodine manufacturing equipment, such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> blender, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, hoppers, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were discolored and rusty. Furthermore, your firm hired a third party to \u003Cstrong>(b)(4)\u003C\u002Fstrong> your equipment to remove corrosion and rust \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Given that you must \u003Cstrong>(b)(4)\u003C\u002Fstrong> corrosion from product contact surfaces \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your contact surfaces are deficient as they can lead to contamination of your product, specifically, particulate matter (e.g., rust).\u003C\u002Fp>\n\n\u003Cp>Additionally, you use trays to further process your product during a \u003Cstrong>(b)(4)\u003C\u002Fstrong> stage. During this processing, you wrap the trays with plastic liners. These plastic liners come into direct contact with povidone. FDA investigators observed the plastic liners were tattered and torn, exposing product to plastic particulate matter.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is adequate to remove corrosion and that you would evaluate the use of plastic liners. Your response is inadequate, because it lacked scientific justification or supportive documentation for your assertion that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is adequate. Furthermore, FDA raised these concerns during the December 2019 inspection and July 2020 regulatory meeting, and you have failed to adequately address them.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Full evaluation of materials of construction of all drug contact surfaces in the facility, with specific focus on additive, absorptive, or reactive factors, and whether they can lead to contamination of the drug distributed.\u003Cbr>\n\u003Cbr>\n• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional API CGMP guidance\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at \u003Ca>https:\u002F\u002Fwww.fda.Q:ov\u002Fdownloads\u002FDrugs\u002F...\u002FGuidances\u002Fucm073497.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP consultant recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your product. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter above (WL #615153). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Richard A. Gilbert\n\nRecipient Title\n\nPresident\n\nMarcus Research Laboratory, Inc.\n\n1820 Delmar Boulevard\n\nSaint Louis, MO 63103\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSeptember 30, 2021\n\nWARNING LETTER\n\nWL #615153\n\nDear Mr. Gilbert:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marcus Research Laboratory, Inc., FEI 1950348, at 1820 Delmar Blvd., Saint Louis, Missouri 63103, from May 3, to May 14, 2021.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your June 4, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to have the procedures and processes necessary to ensure the API manufactured at your facility meet established specifications for quality and purity.\n\nYour firm manufactures povidone iodine (PVP-I), API which may be used by your customers to produce presurgical preparatory products. During the inspection, we observed that your Quality Unit (QU) released API lots 100017872R and 100017911C without adequate procedures and processes to ensure that critical deviations are investigated and resolved.\n\nDuring the production of PVP-I lot 100017872R, on March 4, 2020, your production personnel observed PVP-I in reactor cabinet (b)(4) was smoldering. In response to the risk of imminent fire, production personnel used a fire extinguisher. Due to this incident, production did not proceed as normal. Associated drugs experienced inconsistent temperature exposure and additional processing and hold times. Your firm only tested the affected drums of material for percent of available iodine and released them for further processing.\n\nSimilarly, on August 18, 2020 during the production of PVP-I lot 100017911C, your production personnel noted reactor cabinet (b)(4) was smoking. Production was ceased, and the material was held in unknown conditions. Your firm again, solely tested the affected drums of material for percent available iodine and released them for further processing.\n\nIn both instances, your firm created deviation reports but released drugs based solely on composite results of percent available iodine. Your drugs were exposed to excess heat, fire, smoke, and debris. Additional contaminants or other particulates from the use of the fire extinguisher may have also compromised the material. In addition, the associated drugs experienced processing parameters beyond the normal validated state.\n\nYour firm did not perform additional testing on lots 100017872R and 100017911C to confirm that the API was not contaminated with harmful particulate matter or other contamination. Additionally, your firm lacked a risk or impact assessment to evaluate the exposure of the API to the extraneous debris or contamination resulting from the incidents. The QU released lots 100017872R and 100017911C without ensuring the critical deviation was fully resolved, and any residual chemical contaminants and particulate risks were fully addressed.\n\nIn your response, you stated that you are “currently seeking advice from a consultant to determine the best path forward on addressing this matter.” Your response is inadequate. You did not provide any supporting documentation that evaluated the impacted lots that you released. Specifically, you did not provide supporting documentation that would ensure the material was free of potentially harmful particulate matter and other extraneous contamination given the intended use of the API, including the potential for use in sterile drug products.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provide concurrent stability data for the affected lots 100017872R and 100017911C.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• Your action plan to address any product quality or patient safety risks for batches of povidone iodine in U.S. distribution, including potential customer notifications and recalls or market withdrawals.\n\n2. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\n\nYour equipment construction was inadequate because your product contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. During the inspection, we observed that critical povidone iodine manufacturing equipment, such as the (b)(4) blender, (b)(4), hoppers, and (b)(4), were discolored and rusty. Furthermore, your firm hired a third party to (b)(4) your equipment to remove corrosion and rust (b)(4). Given that you must (b)(4) corrosion from product contact surfaces (b)(4), your contact surfaces are deficient as they can lead to contamination of your product, specifically, particulate matter (e.g., rust).\n\nAdditionally, you use trays to further process your product during a (b)(4) stage. During this processing, you wrap the trays with plastic liners. These plastic liners come into direct contact with povidone. FDA investigators observed the plastic liners were tattered and torn, exposing product to plastic particulate matter.\n\nIn your response, you stated that (b)(4) is adequate to remove corrosion and that you would evaluate the use of plastic liners. Your response is inadequate, because it lacked scientific justification or supportive documentation for your assertion that (b)(4) is adequate. Furthermore, FDA raised these concerns during the December 2019 inspection and July 2020 regulatory meeting, and you have failed to adequately address them.\n\nIn response to this letter, provide:\n\n• Full evaluation of materials of construction of all drug contact surfaces in the facility, with specific focus on additive, absorptive, or reactive factors, and whether they can lead to contamination of the drug distributed.\n\n• Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nAdditional API CGMP guidance\n\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.Q:ov\u002Fdownloads\u002FDrugs\u002F...\u002FGuidances\u002Fucm073497.pdf.\n\nCGMP consultant recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations and assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility\u002Fin connection with your product. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter above (WL #615153). If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations III","Marcus Research Laboratory, Inc.","marcus-research-laboratory-inc-615153-09302021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarcus-research-laboratory-inc-615153-09302021","2026-10-26T08:09:20.315764+00:00","Closed Out","2021-10-19","615153","2024-10-04","Mr. Richard A. Gilbert","2026-08-20T02:31:11.561+00:00","UPS","2021-09-30",{"id":152,"raw":153,"subject":159,"body_html":160,"body_text":161,"firm_name":162,"letter_id":163,"created_at":86,"fei_number":19,"letter_url":164,"updated_at":165,"action_type":22,"case_status":23,"posted_date":166,"marcs_cms_no":167,"product_type":26,"closeout_date":19,"issuing_office":157,"recipient_name":168,"body_fetched_at":169,"delivery_method":170,"recipient_title":19,"reference_number":171,"action_taken_date":172,"medical_device_id":19,"response_letter_date":19},1780,[154,155,156,157,158,13,13,13],"\u003Ctime datetime=\"2023-10-31T13:20:00Z\">10\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-20T04:00:00Z\">10\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsamm-solutions-inc-dba-bts-research-663898-10202023\">Samm Solutions, Inc., d.b.a. BTS Research\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies\u003Cbr \u002F>\r\n","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HFD-45-10-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Usama M. Abunadi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Samm Solutions, Inc., d.b.a. BTS Research\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9990 Mesa Rim Road, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Abunadi:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 27 and July 8, 2022. Investigator Theressa B. Smith, representing FDA, reviewed the role of Samm Solutions, Inc., d.b.a. BTS Research, as the testing facility of the following nonclinical laboratory studies:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;(formerly performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fli>\n\t\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations (CFR), part 58 [21 CFR 58] – Good Laboratory Practice (GLP) regulations.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Smith presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your two written responses to the Form FDA 483, dated July 29, 2022, and November 23, 2022.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. The study director failed to assure that all experimental data were accurately recorded and verified, and failed to assure unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented [21 CFR 58.33(b) and (c)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The study director of each nonclinical laboratory study has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation, and reporting of results, and represents the single point of study control. The study director shall ensure that all experimental data, including observations of unanticipated responses of the test system, are accurately recorded and verified; and shall ensure that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and that corrective action is taken and documented. The study directors at your testing facility for Protocols&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to adhere to these requirements.\u003C\u002Fp>\n\n\u003Cp>Specifically, the study directors for both nonclinical laboratory studies failed to accurately record and verify analytical results for clinical pathology. They also failed to note unforeseen circumstances that may have affected the quality and integrity of the study. Examples include but are not limited to the following:\u003C\u002Fp>\n\n\u003Cp>a. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> required clinical pathology investigations on the day of necropsy (Day 28 of the study) for animals designated as Main, including evaluation of clinical chemistry parameters (for example, serum phosphorus and alkaline phosphatase) and coagulation parameters (activated partial thromboplastin time (PTT), prothrombin time (PT), and fibrinogen). However, the following clinical pathology investigations were not evaluated on the day of necropsy for the following Main animals:\u003C\u002Fp>\n\n\u003Cp>i. Serum phosphorus was not evaluated for Group 1 (Animals 1001 through 1010 and Animals 1501 through 1510) on Day 28, April 12, 2021.\u003C\u002Fp>\n\n\u003Cp>ii. Serum phosphorus and alkaline phosphatase were not evaluated for Group 2 (Animals 2001 through 2010 and Animals 2501 through 2510) on Day 28, April 13, 2021.\u003C\u002Fp>\n\n\u003Cp>In your written responses to the Form FDA 483, you stated that phosphorous and alkaline phosphatase were not evaluated because of the unavailability of the reagents needed and your having only expired reagents on hand. However, there is no documentation that the study director noted these unforeseen circumstances when they occurred. Subsequently, on June 15 and 16, 2021, serum phosphorus and alkaline phosphatase for the animals in Groups 1 and 2 were analyzed.\u003C\u002Fp>\n\n\u003Cp>However, although these animals were subsequently analyzed, the serum phosphorus analysis results of the samples in the final report for most Group 1 animals do not match the analysis results listed on the laboratory worksheet. In your written responses, you state that it was not possible to obtain phosphorus data for these animals. Additionally, in your written responses, you state that alkaline phosphatase results were not available for Animals 1003 and 1505; however, the June 15, 2021, laboratory results report alkaline phosphatase results for these animals.\u003C\u002Fp>\n\n\u003Cp>iii. Activated partial thromboplastin time (PTT), prothrombin time (PT), and fibrinogen for Group 3 (Animals 3504 through 3510) were not evaluated on Day 28, April 20, 2021. These coagulation parameters were flagged with error codes (Early Reaction Error, Measurement Error), and no results were reported in the final report.\u003C\u002Fp>\n\n\u003Cp>In your written responses, you stated that the coagulation analyzer was not functioning properly and was not providing results. You further stated that the technician did not report the lack of results to the study director because he planned to rerun the samples. You also stated that, on June 21 and June 23, 2021, repeat testing occurred for Animals 3504 through 3510, but results were not available because the operator did not have enough sample to test. Additionally, some samples from Group 1 (Animals 1001 through 1015 and Animals 1501 through 1515) and Group 4 (Animals 4011 through 4015 and Animals 4511 through 4515) were reanalyzed on June 21 and June 23, 2021. There is no documentation that the study director noted the unforeseen circumstances (that is, the problems with the coagulation analyzer, the insufficient quantity of samples for analysis, and the repeat analysis of samples) when they occurred.\u003C\u002Fp>\n\n\u003Cp>b. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> required clinical pathology investigations on the day of necropsy (Day 183 of the study), including clinical chemistry parameters (for example, gamma glutamyl transferase (GGT)). However, GGT was not evaluated for study animals on Day 183, March 14, 2021. GGT parameters were out of range, and all animals were attributed with a minimal GGT value of &lt;4.0 U\u002FL, without being retested.\u003C\u002Fp>\n\n\u003Cp>In your written responses, you explained that the technician documented in the raw data that GGT control was ignored due to abundant past evidence of very minimal (practically undetectable) amounts of GGT in Sprague Dawley rats; and that, for this reason, he proceeded with the rest of the measurements, disregarding the GGT. You also noted that at the time the study was conducted, the study director was not required to document the review date of study data.\u003C\u002Fp>\n\n\u003Cp>In your written responses to the Form FDA 483, you stated that report amendments have been or will be issued for Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that these amendments will include a revised review and protocol deviations. You also stated that the following SOPs have been revised: (1) SOP A12.04, “Review and Verification of Data,” and (2) SOP G45.04, “Calibration, Use, and Maintenance of the RX Imola Clinical Chemistry Analyzer,” to detail any special circumstances related to the exclusion of any parameter.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the corrective and preventive actions that your testing facility has taken and plans to take; however, your response is inadequate because you did not provide complete raw data that support reanalysis of clinical pathology investigations and the results included in the amended reports. We cannot undertake an informed evaluation of your written response because you did not provide complete raw data.\u003C\u002Fp>\n\n\u003Cp>The study director of each nonclinical laboratory study has overall responsibility for the technical conduct of the study, as well as the interpretation, analysis, documentation, and reporting of results, and represents the single point of study control. Because the study directors at your testing facility failed to ensure that experimental data were accurately recorded and verified; that unforeseen circumstances were documented when they occurred; and that corrective action was taken and documented, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81 (a)]; The final study report did not include a description of all circumstances that may have affected the quality and integrity of the data [21 CFR 58.185 (a)(9)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The study director must authorize all deviations from standard operating procedures in a study and document all study deviations in the raw data. Additionally, the study director must include in the final study report a description of all circumstances that may have affected the quality and integrity of the data. Similarly, as required by SOP A14.0, “Nonclinical Study Report Generation and Approval,” final study reports shall also include amendments and deviations forms issued during the study that include a description of all circumstances that may have affected the quality or integrity of the data. The study directors at your testing facility did not adhere to these requirements. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. As required by SOP A14.0 the following deviation forms were required to be included in the final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, these were not included in the final study report:\u003C\u002Fp>\n\n\u003Cp>1. Deviation form, “SOP Deviation 1,” describing the following deviations from SOP B01.03 (Defining, Manually Reporting, and Correcting Raw Data) and SOP F07.01 (Dose Formation Analysis Range):\u003C\u002Fp>\n\n\u003Cp>(a) Eye examination for Animal 3502 was not documented at the time of the actual eye examination.\u003C\u002Fp>\n\n\u003Cp>(b) The batch number of the vehicle was incorrectly documented as the lot number on formulation sheets.\u003C\u002Fp>\n\n\u003Cp>(c) Mean concentration for the formulation analysis samples for Groups 2, 3, and 4 were all outside of the acceptable theoretical difference range.\u003C\u002Fp>\n\n\u003Cp>2. Deviation form, “SOP Deviation 2,” describing a deviation from SOP B01.03: Temperatures were not recorded for the refrigerator used to store test article in December 2018.\u003C\u002Fp>\n\n\u003Cp>b. Deviation from SOP A03 (“Archival Procedures”), which requires submission of the Archive Submission Form (submission worksheet) to record physical data and documentation pertaining to the assigned GLP study submitted to the archive, was not authorized by the study director and was not documented in the raw data. The study was also not recorded on the electronic archive log. These deviations were not included in the final study report.\u003C\u002Fp>\n\n\u003Cp>c. Deviation of the protocol requirement to retain target tissues at necropsy on Day 183, for histology processing and histopathological evaluation of tissues from certain Main animals. For example, histology worksheets and individual gross and microscopic reports document repeated findings in which tissues were missing upon processing for Main animals, including Animals 4008, 4014, and 4501. These deviations were not included in the final study report.\u003C\u002Fp>\n\n\u003Cp>In your written responses, you acknowledge that the SOP deviations and the missing tissues deviation should have been included in the final study report. You stated that SOP A14.04 was revised to reflect the requirement to file all deviations in the final study report; that training on SOP revisions was conducted; and that the SOP and missing tissue deviations have been or will be included in an amended final report.\u003C\u002Fp>\n\n\u003Cp>You also stated in your written responses that during the time when the archival storage was being relocated, the form (submission worksheet) was not used to log the archiving, but the archiving process was followed. You included an e-mail from the study coordinator to the QAU to note the submission of the final report and raw data for archiving.\u003C\u002Fp>\n\n\u003Cp>While we acknowledge your corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, you did not provide a list documenting which raw data or documents were submitted to the archive for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you did not provide the signed amended final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> referenced in your November 23, 2022, response. Without these details, we are unable to determine whether your corrective actions appear adequate to help prevent similar violations in the future. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations.\u003C\u002Fp>\n\n\u003Cp>Failure to include a description of all circumstances that may affect the quality and integrity of the data in the final study report, including SOP and protocol deviations, raises concerns about the quality and integrity of the study records and data generated from the nonclinical laboratory studies conducted at your testing facility. The records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. The quality assurance unit (QAU) failed to assure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35 (b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\u003C\u002Fp>\n\n\u003Cp>Specifically, the following observations\u002Fdata were not accurately documented in the final study reports for Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>a. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Final Report: \u003Cstrong>(b)(4)\u003C\u002Fstrong>):\u003C\u002Fp>\n\n\u003Cp>i. Clinical observations of increased activity on Day 42 (April 30, 2021) for Animal 4515 was not reflected in the final study report. We note that the Form FDA 483 inaccurately identified this animal as Animal 4514.\u003C\u002Fp>\n\n\u003Cp>ii. Additional dosing of Group 2 animals (Animals 2001 through 2010 and Animals 2501 through 2510) on Day 1 (March 17, 2021) was not reflected appropriately in Appendix 1 (Individual Animal Estimated Dose Levels) of the final study report.\u003C\u002Fp>\n\n\u003Cp>b. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Final Report: \u003Cstrong>(b)(4)\u003C\u002Fstrong>):\u003C\u002Fp>\n\n\u003Cp>i. The date of study director reassignment, July 8, 2020, was inaccurately recorded in the final study report as July 8, 2018.\u003C\u002Fp>\n\n\u003Cp>ii. Dates for the administration of the test article and vehicle for the animals in this study are inaccurate in several sections of the final report. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; (1) Group 1 animals were dosed on June 12, 2018; however, the date recorded for this respective time point in the final report was June 11, 2018.\u003Cbr>\n&nbsp; (2) Group 4 animals were dosed on June 15, 2018; however, the date recorded for this respective time point in the final report was June 14, 2018.\u003C\u002Fp>\n\n\u003Cp>iii. Unscheduled clinical observations that occurred between October 9 and 10, 2018, regarding masses\u002Flumps\u002Fbumps found in animals, including Animals 4018, 4020, 4021, 4024, and 4027, were not reported in the final study report.\u003C\u002Fp>\n\n\u003Cp>iv. There are discrepancies in the record for the dates and circumstances of the deaths of Animal 1006 (sacrificed date: June 20, 2018; actually found dead on June 25, 2018), Animal 3009 (sacrificed date: June 25, 2018; actually found dead on June 23, 2018), and Animal 1511 (sacrificed date: July 7, 2018; actually found dead on July 26, 2018), as recorded in the final report in Text Table 9: Found Dead and Early Sacrifice Animals, and as recorded on the Necropsy Tissue Collection Form and in the Pristima data (Date of Death).\u003C\u002Fp>\n\n\u003Cp>v. The Death Status Report maintained in the Pristima software for Animal 4529 reflects an unscheduled death on December 17, 2018; however, the death of this animal is not reported in the final study report.\u003C\u002Fp>\n\n\u003Cp>In your written responses to the Form FDA 483, regarding the observations related to Protocol&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> (Final Report: \u003Cstrong>(b)(4)\u003C\u002Fstrong>), you acknowledged that the QA auditor failed to ensure that certain raw data were accurately reflected in the final study report. You stated that the QA auditor inadvertently missed the inclusion of certain raw data and is no longer working for the company. You stated that the final report has been or will be amended to include the raw data.\u003C\u002Fp>\n\n\u003Cp>With respect to observations regarding Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Final Report: \u003Cstrong>(b)(4)\u003C\u002Fstrong>), you acknowledged the observations and stated that as a corrective action, the report has been or will be amended to include accurate or missing data. You also stated that the method for reviewing data will be changed to a more comprehensive review that includes a sampling technique for a number of animals and their end points from start to finish of the study, rather than modulated review of forms. Last, you indicated that the QAU inspection SOP C06 will be revised to include guidance on the sampling inspection for raw data by following selected animals from start to end of study, including all end points. While we acknowledge the actions your site plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan, including the procedures being instituted at your site to ensure compliance, such as the revised SOP C06.\u003C\u002Fp>\n\n\u003Cp>Because the QAU of your testing facility failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. The study director failed to assure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study [21 CFR 58.33(f)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The study director must ensure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study.\u003Cbr>\n\u003Cbr>\nThe study directors at your testing facility for both Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to adhere to this requirement. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. For Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the study director failed to ensure that all study records were transferred to the archives at the close of the study. For example, the following documents were reported as having been submitted to the archive on September 10, 2021, but were not maintained in the testing facility’s archives at the close of the study:\u003C\u002Fp>\n\n\u003Cp>(1) Signed protocol amendments\u003Cbr>\n(2) Signed protocol deviations\u003Cbr>\n(3) Final report\u003Cbr>\n(4) Animal Care and Use Protocol\u003Cbr>\n(5) Freezer logs for the equipment used to store the test article\u003C\u002Fp>\n\n\u003Cp>b. For Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the study director failed to ensure that all study records were transferred to the archives at the close of the study. For example, the following three study memos were not submitted to the archives:\u003C\u002Fp>\n\n\u003Cp>(1) A June 6, 2018, memo regarding deviations related to randomization and replacement of animals due to corneal dystrophy\u003Cbr>\n(2) A June 12, 2018, memo regarding renumbering of animals in Groups 2 and 3 and replacement of animals\u003Cbr>\n(3) An undated memo regarding inconsistencies in the measurements of tumor masses in clinical observations\u003C\u002Fp>\n\n\u003Cp>We acknowledge that the finding discussed above regarding the June 12, 2018, and undated memos were not included on the Form FDA 483 you received, and that your written responses therefore do not address these specific issues.\u003C\u002Fp>\n\n\u003Cp>In your written responses to the Form FDA 483, you acknowledged that the study directors for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to ensure that all data were forwarded to the archives. We note that the failure to archive data is a repeat finding from FDA’s June 2019 inspection of your testing facility. With respect to Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that the study director functioned remotely for most of his role and relied on a study coordinator, who is no longer with the firm. With respect to Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you stated that because the archival storage was being relocated, the appropriate forms were not used to log for archiving.\u003C\u002Fp>\n\n\u003Cp>As a corrective action, you stated that the study director has been retrained on procedures to ensure the proper archiving of study records. You also stated in your written response that a planned corrective action is to have the QAU monitor the archiving process for all future studies. While we acknowledge the actions your site has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, you did not provide sufficient details about how the study director will comply with archiving requirements to prevent the recurrence of such findings in future studies. Also, you did not provide the training record on proper archiving for the study director. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations.\u003C\u002Fp>\n\n\u003Cp>Failure to ensure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study raises concerns about the integrity of study records and data.\u003C\u002Fp>\n\n\u003Cp>As evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the study directors and the QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical studies. As a result, FDA is concerned about the validity of the nonclinical data generated by your testing facility.\u003C\u002Fp>\n\n\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under part 58, you are responsible for ensuring that those nonclinical laboratory studies are conducted in accordance with FDA regulations to ensure the quality and integrity of the study data. Your failure to conduct the nonclinical studies in accordance with the study protocol, SOPs, and FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe that you have complied with the FD&amp;C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Miah Jung, Pharm.D., M.S.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n10\u002F20\u002F2023 10:52:35 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n24-HFD-45-10-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nUsama M. Abunadi\n\nRecipient Title\n\nPresident and CEO\n\nSamm Solutions, Inc., d.b.a. BTS Research\n\n9990 Mesa Rim Road, Suite 100\n\nSan Diego, CA 92121\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Abunadi:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between June 27 and July 8, 2022. Investigator Theressa B. Smith, representing FDA, reviewed the role of Samm Solutions, Inc., d.b.a. BTS Research, as the testing facility of the following nonclinical laboratory studies:\n\nProtocol (b)(4): \"(b)(4) of the investigational drug (b)(4), performed for (b)(4) (formerly performed for (b)(4))\n\nProtocol (b)(4): “(b)(4),” of investigational drug (b)(4), performed for (b)(4)\n\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations (CFR), part 58 [21 CFR 58] – Good Laboratory Practice (GLP) regulations.\n\nAt the conclusion of the inspection, Investigator Smith presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your two written responses to the Form FDA 483, dated July 29, 2022, and November 23, 2022.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\n\n1. The study director failed to assure that all experimental data were accurately recorded and verified, and failed to assure unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and corrective action is taken and documented [21 CFR 58.33(b) and (c)].\n\nThe study director of each nonclinical laboratory study has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation, and reporting of results, and represents the single point of study control. The study director shall ensure that all experimental data, including observations of unanticipated responses of the test system, are accurately recorded and verified; and shall ensure that unforeseen circumstances that may affect the quality and integrity of the nonclinical laboratory study are noted when they occur, and that corrective action is taken and documented. The study directors at your testing facility for Protocols (b)(4) and (b)(4) failed to adhere to these requirements.\n\nSpecifically, the study directors for both nonclinical laboratory studies failed to accurately record and verify analytical results for clinical pathology. They also failed to note unforeseen circumstances that may have affected the quality and integrity of the study. Examples include but are not limited to the following:\n\na. Protocol (b)(4) required clinical pathology investigations on the day of necropsy (Day 28 of the study) for animals designated as Main, including evaluation of clinical chemistry parameters (for example, serum phosphorus and alkaline phosphatase) and coagulation parameters (activated partial thromboplastin time (PTT), prothrombin time (PT), and fibrinogen). However, the following clinical pathology investigations were not evaluated on the day of necropsy for the following Main animals:\n\ni. Serum phosphorus was not evaluated for Group 1 (Animals 1001 through 1010 and Animals 1501 through 1510) on Day 28, April 12, 2021.\n\nii. Serum phosphorus and alkaline phosphatase were not evaluated for Group 2 (Animals 2001 through 2010 and Animals 2501 through 2510) on Day 28, April 13, 2021.\n\nIn your written responses to the Form FDA 483, you stated that phosphorous and alkaline phosphatase were not evaluated because of the unavailability of the reagents needed and your having only expired reagents on hand. However, there is no documentation that the study director noted these unforeseen circumstances when they occurred. Subsequently, on June 15 and 16, 2021, serum phosphorus and alkaline phosphatase for the animals in Groups 1 and 2 were analyzed.\n\nHowever, although these animals were subsequently analyzed, the serum phosphorus analysis results of the samples in the final report for most Group 1 animals do not match the analysis results listed on the laboratory worksheet. In your written responses, you state that it was not possible to obtain phosphorus data for these animals. Additionally, in your written responses, you state that alkaline phosphatase results were not available for Animals 1003 and 1505; however, the June 15, 2021, laboratory results report alkaline phosphatase results for these animals.\n\niii. Activated partial thromboplastin time (PTT), prothrombin time (PT), and fibrinogen for Group 3 (Animals 3504 through 3510) were not evaluated on Day 28, April 20, 2021. These coagulation parameters were flagged with error codes (Early Reaction Error, Measurement Error), and no results were reported in the final report.\n\nIn your written responses, you stated that the coagulation analyzer was not functioning properly and was not providing results. You further stated that the technician did not report the lack of results to the study director because he planned to rerun the samples. You also stated that, on June 21 and June 23, 2021, repeat testing occurred for Animals 3504 through 3510, but results were not available because the operator did not have enough sample to test. Additionally, some samples from Group 1 (Animals 1001 through 1015 and Animals 1501 through 1515) and Group 4 (Animals 4011 through 4015 and Animals 4511 through 4515) were reanalyzed on June 21 and June 23, 2021. There is no documentation that the study director noted the unforeseen circumstances (that is, the problems with the coagulation analyzer, the insufficient quantity of samples for analysis, and the repeat analysis of samples) when they occurred.\n\nb. Protocol (b)(4) required clinical pathology investigations on the day of necropsy (Day 183 of the study), including clinical chemistry parameters (for example, gamma glutamyl transferase (GGT)). However, GGT was not evaluated for study animals on Day 183, March 14, 2021. GGT parameters were out of range, and all animals were attributed with a minimal GGT value of \u003C4.0 U\u002FL, without being retested.\n\nIn your written responses, you explained that the technician documented in the raw data that GGT control was ignored due to abundant past evidence of very minimal (practically undetectable) amounts of GGT in Sprague Dawley rats; and that, for this reason, he proceeded with the rest of the measurements, disregarding the GGT. You also noted that at the time the study was conducted, the study director was not required to document the review date of study data.\n\nIn your written responses to the Form FDA 483, you stated that report amendments have been or will be issued for Protocols (b)(4) and (b)(4), and that these amendments will include a revised review and protocol deviations. You also stated that the following SOPs have been revised: (1) SOP A12.04, “Review and Verification of Data,” and (2) SOP G45.04, “Calibration, Use, and Maintenance of the RX Imola Clinical Chemistry Analyzer,” to detail any special circumstances related to the exclusion of any parameter.\n\nWe acknowledge the corrective and preventive actions that your testing facility has taken and plans to take; however, your response is inadequate because you did not provide complete raw data that support reanalysis of clinical pathology investigations and the results included in the amended reports. We cannot undertake an informed evaluation of your written response because you did not provide complete raw data.\n\nThe study director of each nonclinical laboratory study has overall responsibility for the technical conduct of the study, as well as the interpretation, analysis, documentation, and reporting of results, and represents the single point of study control. Because the study directors at your testing facility failed to ensure that experimental data were accurately recorded and verified; that unforeseen circumstances were documented when they occurred; and that corrective action was taken and documented, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility.\n\n2. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81 (a)]; The final study report did not include a description of all circumstances that may have affected the quality and integrity of the data [21 CFR 58.185 (a)(9)].\n\nThe study director must authorize all deviations from standard operating procedures in a study and document all study deviations in the raw data. Additionally, the study director must include in the final study report a description of all circumstances that may have affected the quality and integrity of the data. Similarly, as required by SOP A14.0, “Nonclinical Study Report Generation and Approval,” final study reports shall also include amendments and deviations forms issued during the study that include a description of all circumstances that may have affected the quality or integrity of the data. The study directors at your testing facility did not adhere to these requirements. Specifically:\n\na. As required by SOP A14.0 the following deviation forms were required to be included in the final study report for Protocol (b)(4); however, these were not included in the final study report:\n\n1. Deviation form, “SOP Deviation 1,” describing the following deviations from SOP B01.03 (Defining, Manually Reporting, and Correcting Raw Data) and SOP F07.01 (Dose Formation Analysis Range):\n\n(a) Eye examination for Animal 3502 was not documented at the time of the actual eye examination.\n\n(b) The batch number of the vehicle was incorrectly documented as the lot number on formulation sheets.\n\n(c) Mean concentration for the formulation analysis samples for Groups 2, 3, and 4 were all outside of the acceptable theoretical difference range.\n\n2. Deviation form, “SOP Deviation 2,” describing a deviation from SOP B01.03: Temperatures were not recorded for the refrigerator used to store test article in December 2018.\n\nb. Deviation from SOP A03 (“Archival Procedures”), which requires submission of the Archive Submission Form (submission worksheet) to record physical data and documentation pertaining to the assigned GLP study submitted to the archive, was not authorized by the study director and was not documented in the raw data. The study was also not recorded on the electronic archive log. These deviations were not included in the final study report.\n\nc. Deviation of the protocol requirement to retain target tissues at necropsy on Day 183, for histology processing and histopathological evaluation of tissues from certain Main animals. For example, histology worksheets and individual gross and microscopic reports document repeated findings in which tissues were missing upon processing for Main animals, including Animals 4008, 4014, and 4501. These deviations were not included in the final study report.\n\nIn your written responses, you acknowledge that the SOP deviations and the missing tissues deviation should have been included in the final study report. You stated that SOP A14.04 was revised to reflect the requirement to file all deviations in the final study report; that training on SOP revisions was conducted; and that the SOP and missing tissue deviations have been or will be included in an amended final report.\n\nYou also stated in your written responses that during the time when the archival storage was being relocated, the form (submission worksheet) was not used to log the archiving, but the archiving process was followed. You included an e-mail from the study coordinator to the QAU to note the submission of the final report and raw data for archiving.\n\nWhile we acknowledge your corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, you did not provide a list documenting which raw data or documents were submitted to the archive for Protocol (b)(4). In addition, you did not provide the signed amended final study report for Protocol (b)(4) referenced in your November 23, 2022, response. Without these details, we are unable to determine whether your corrective actions appear adequate to help prevent similar violations in the future. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations.\n\nFailure to include a description of all circumstances that may affect the quality and integrity of the data in the final study report, including SOP and protocol deviations, raises concerns about the quality and integrity of the study records and data generated from the nonclinical laboratory studies conducted at your testing facility. The records and final study report of an investigation are crucial to the reconstruction of events leading to the collection and reporting of the data and must reflect the procedure and condition of the study. The information in these essential documents forms the basis for establishing scientific interpretations and conclusions and must therefore reflect all circumstances affecting the quality and integrity of the data.\n\n3. The quality assurance unit (QAU) failed to assure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35 (b)(6)].\n\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\n\nSpecifically, the following observations\u002Fdata were not accurately documented in the final study reports for Protocols (b)(4) and (b)(4):\n\na. Protocol (b)(4) (Final Report: (b)(4)):\n\ni. Clinical observations of increased activity on Day 42 (April 30, 2021) for Animal 4515 was not reflected in the final study report. We note that the Form FDA 483 inaccurately identified this animal as Animal 4514.\n\nii. Additional dosing of Group 2 animals (Animals 2001 through 2010 and Animals 2501 through 2510) on Day 1 (March 17, 2021) was not reflected appropriately in Appendix 1 (Individual Animal Estimated Dose Levels) of the final study report.\n\nb. Protocol (b)(4) (Final Report: (b)(4)):\n\ni. The date of study director reassignment, July 8, 2020, was inaccurately recorded in the final study report as July 8, 2018.\n\nii. Dates for the administration of the test article and vehicle for the animals in this study are inaccurate in several sections of the final report. For example:\n\n(1) Group 1 animals were dosed on June 12, 2018; however, the date recorded for this respective time point in the final report was June 11, 2018.\n\n(2) Group 4 animals were dosed on June 15, 2018; however, the date recorded for this respective time point in the final report was June 14, 2018.\n\niii. Unscheduled clinical observations that occurred between October 9 and 10, 2018, regarding masses\u002Flumps\u002Fbumps found in animals, including Animals 4018, 4020, 4021, 4024, and 4027, were not reported in the final study report.\n\niv. There are discrepancies in the record for the dates and circumstances of the deaths of Animal 1006 (sacrificed date: June 20, 2018; actually found dead on June 25, 2018), Animal 3009 (sacrificed date: June 25, 2018; actually found dead on June 23, 2018), and Animal 1511 (sacrificed date: July 7, 2018; actually found dead on July 26, 2018), as recorded in the final report in Text Table 9: Found Dead and Early Sacrifice Animals, and as recorded on the Necropsy Tissue Collection Form and in the Pristima data (Date of Death).\n\nv. The Death Status Report maintained in the Pristima software for Animal 4529 reflects an unscheduled death on December 17, 2018; however, the death of this animal is not reported in the final study report.\n\nIn your written responses to the Form FDA 483, regarding the observations related to Protocol (b)(4) (Final Report: (b)(4)), you acknowledged that the QA auditor failed to ensure that certain raw data were accurately reflected in the final study report. You stated that the QA auditor inadvertently missed the inclusion of certain raw data and is no longer working for the company. You stated that the final report has been or will be amended to include the raw data.\n\nWith respect to observations regarding Protocol (b)(4) (Final Report: (b)(4)), you acknowledged the observations and stated that as a corrective action, the report has been or will be amended to include accurate or missing data. You also stated that the method for reviewing data will be changed to a more comprehensive review that includes a sampling technique for a number of animals and their end points from start to finish of the study, rather than modulated review of forms. Last, you indicated that the QAU inspection SOP C06 will be revised to include guidance on the sampling inspection for raw data by following selected animals from start to end of study, including all end points. While we acknowledge the actions your site plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan, including the procedures being instituted at your site to ensure compliance, such as the revised SOP C06.\n\nBecause the QAU of your testing facility failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n\n4. The study director failed to assure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study [21 CFR 58.33(f)].\n\nThe study director must ensure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study.\n\nThe study directors at your testing facility for both Protocols (b)(4) and (b)(4) failed to adhere to this requirement. Specifically:\n\na. For Protocol (b)(4), the study director failed to ensure that all study records were transferred to the archives at the close of the study. For example, the following documents were reported as having been submitted to the archive on September 10, 2021, but were not maintained in the testing facility’s archives at the close of the study:\n\n(1) Signed protocol amendments\n\n(2) Signed protocol deviations\n\n(3) Final report\n\n(4) Animal Care and Use Protocol\n\n(5) Freezer logs for the equipment used to store the test article\n\nb. For Protocol (b)(4), the study director failed to ensure that all study records were transferred to the archives at the close of the study. For example, the following three study memos were not submitted to the archives:\n\n(1) A June 6, 2018, memo regarding deviations related to randomization and replacement of animals due to corneal dystrophy\n\n(2) A June 12, 2018, memo regarding renumbering of animals in Groups 2 and 3 and replacement of animals\n\n(3) An undated memo regarding inconsistencies in the measurements of tumor masses in clinical observations\n\nWe acknowledge that the finding discussed above regarding the June 12, 2018, and undated memos were not included on the Form FDA 483 you received, and that your written responses therefore do not address these specific issues.\n\nIn your written responses to the Form FDA 483, you acknowledged that the study directors for Protocol (b)(4) and Protocol (b)(4) failed to ensure that all data were forwarded to the archives. We note that the failure to archive data is a repeat finding from FDA’s June 2019 inspection of your testing facility. With respect to Protocol (b)(4), you stated that the study director functioned remotely for most of his role and relied on a study coordinator, who is no longer with the firm. With respect to Protocol (b)(4), you stated that because the archival storage was being relocated, the appropriate forms were not used to log for archiving.\n\nAs a corrective action, you stated that the study director has been retrained on procedures to ensure the proper archiving of study records. You also stated in your written response that a planned corrective action is to have the QAU monitor the archiving process for all future studies. While we acknowledge the actions your site has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, you did not provide sufficient details about how the study director will comply with archiving requirements to prevent the recurrence of such findings in future studies. Also, you did not provide the training record on proper archiving for the study director. Without this information, we cannot undertake an informed evaluation of your written response, and it is not clear whether your corrective and preventive actions will adequately ensure that ongoing and future studies will be conducted in compliance with applicable FDA regulations.\n\nFailure to ensure that all raw data, documentation, protocols, specimens, and final reports are transferred to the archives during or at the close of the study raises concerns about the integrity of study records and data.\n\nAs evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the study directors and the QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical studies. As a result, FDA is concerned about the validity of the nonclinical data generated by your testing facility.\n\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under part 58, you are responsible for ensuring that those nonclinical laboratory studies are conducted in accordance with FDA regulations to ensure the quality and integrity of the study data. Your failure to conduct the nonclinical studies in accordance with the study protocol, SOPs, and FDA regulations raises concerns about the validity and integrity of the data collected at your site.\n\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to adequately address this matter may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant FDA regulations, please include your reasoning and any supporting information for our consideration.\n\nIf you have any questions, please call Miah Jung, Pharm.D., M.S., at 240-402-3728. Alternatively, you may e-mail FDA at CDER-OSI-Communications@fda.hhs.gov.\n\nYour written response and any pertinent documentation should be addressed to:\n\nMiah Jung, Pharm.D., M.S.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely yours,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n10\u002F20\u002F2023 10:52:35 AM","Samm Solutions, Inc., d.b.a. BTS Research","samm-solutions-inc-dba-bts-research-663898-10202023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsamm-solutions-inc-dba-bts-research-663898-10202023","2026-10-26T08:09:53.179209+00:00","2023-10-31","663898","Usama M. Abunadi","2026-08-20T00:34:16.027+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","24-HFD-45-10-01","2023-10-20",{"id":174,"raw":175,"subject":180,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":140,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":189,"closeout_date":19,"issuing_office":179,"recipient_name":190,"body_fetched_at":191,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},3260,[176,177,178,179,180,13,13,13],"\u003Ctime datetime=\"2021-07-13T13:20:00Z\">07\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-01T04:00:00Z\">07\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021\">Biomedical Research Laboratories, LLC\u003C\u002Fa>","Office of Human and Animal Food Operations –West Division 5","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher Jacob\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomedical Research Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7590 Fay Ave Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037-4885\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations –West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>July 1, 2021\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 612831\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jacob:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Calm Legs\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Calm Legs product page:\u003Cbr>\n&nbsp; o “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\u003Cbr>\n&nbsp; o “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\u003Cbr>\n&nbsp; o “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\u003Cbr>\n&nbsp; o “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\u003Cbr>\n&nbsp; o “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\u003Cbr>\n&nbsp; o “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\u003Cbr>\n&nbsp; o “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\u003Cbr>\n&nbsp; o “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\u003Cbr>\n• On the blog post “Hope for RLS Sufferers”:\u003Cbr>\n&nbsp; o “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\u003Cbr>\n&nbsp; o “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\u003Cbr>\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\u003Cbr>\n&nbsp; o “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\u003Cbr>\n• On the blog post “How Stress Impacts RLS”:\u003Cbr>\n&nbsp; o “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\u003Cbr>\n• On the blog post “What is Restless Legs Syndrome?”:\u003Cbr>\n&nbsp; o “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\u003Cbr>\nOn your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\u003Cbr>\n• An embedded YouTube video includes the following claims:\u003Cbr>\n&nbsp; o “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\u003Cbr>\n&nbsp; o “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\u003C\u002Fp>\n\n\u003Cp>On the Native Origins Facebook page:\u003Cbr>\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\u003Cbr>\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\u003Cbr>\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\u003Cbr>\n• “Natural Remedy for RLS”\u003Cbr>\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\u003Cbr>\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Flexify\u003C\u002Fstrong>\u003Cbr>\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\u003Cbr>\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\u003Cbr>\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\u003Cbr>\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\u003Cbr>\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\u003Cbr>\n&nbsp; o “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\u003Cbr>\n&nbsp; o “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\u003Cbr>\n&nbsp; o “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\u003Cbr>\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\u003Cbr>\n&nbsp; o “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Collagen Peptides\u003C\u002Fstrong>\u003Cbr>\nOn your product website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Collagen Peptides product page:\u003Cbr>\n&nbsp; o “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\u003Cbr>\n• On the blog post “What Are the Health Benefits of Collagen?”:\u003Cbr>\n&nbsp; o “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\u003Cbr>\n&nbsp; o “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\u003Cbr>\n• On the blog post “4 Ways to Add Collagen to Your Day”:\u003Cbr>\n&nbsp; o “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\u003Cbr>\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\u003Cbr>\n&nbsp; o “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\u003Cbr>\n• On the blog post “Collagen and Joint Health”:\u003Cbr>\n&nbsp; o “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\u003Cbr>\n&nbsp; o “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohemia\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Prohemia product page:\u003Cbr>\n&nbsp; o “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\u003Cbr>\n&nbsp; o “Prohemia contains several potent antioxidants to reduce inflammation . . .”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\u003Cbr>\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Altitude RX\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Altitude RX product page:\u003Cbr>\n&nbsp; o “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\u003Cbr>\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\u003Cbr>\n&nbsp; o “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\u003Cbr>\n&nbsp; o “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\u003Cbr>\n&nbsp; o “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlsports.com:\u003Cbr>\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\u003Cbr>\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\u003Cbr>\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\u003Cbr>\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\u003Cbr>\n\u003Cbr>\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Take Altitude RX for altitude sickness prevention…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Trimmunity\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Trimmunity product page:\u003Cbr>\n&nbsp; o “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\u003Cbr>\n&nbsp; o “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\u003Cbr>\n&nbsp; o “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\u003Cbr>\n&nbsp; o “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\u003Cbr>\n&nbsp; o “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\u003C\u002Fp>\n\n\u003Cp>Your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 612831 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher Jacob\n\nRecipient Title\n\nCEO\n\nBiomedical Research Laboratories, LLC\n\n7590 Fay Ave Suite 202\n\nLa Jolla, CA 92037-4885\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations –West Division 5\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2021\n\nWL 612831\n\nDear Mr. Jacob:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nCalm Legs\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Calm Legs product page:\n\no “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\n\no “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\n\no “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\n\no “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\n\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\n\no “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\n\no “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\n\no “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\n\no “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\n\n• On the blog post “Hope for RLS Sufferers”:\n\no “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\n\no “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\n\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\n\no “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\n\n• On the blog post “How Stress Impacts RLS”:\n\no “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\n\n• On the blog post “What is Restless Legs Syndrome?”:\n\no “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\n\n• An embedded YouTube video includes the following claims:\n\no “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\n\no “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\n\nOn the Native Origins Facebook page:\n\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\n\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\n\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\n\n• “Natural Remedy for RLS”\n\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\n\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\n\nFlexify\n\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\n\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\n\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\n\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\n\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\n\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\n\no “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\n\no “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\n\no “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\n\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\n\no “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\n\nCollagen Peptides\n\nOn your product website https:\u002F\u002Fnativeorigins.com:\n\n• On the Collagen Peptides product page:\n\no “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\n\n• On the blog post “What Are the Health Benefits of Collagen?”:\n\no “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\n\no “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\n\n• On the blog post “4 Ways to Add Collagen to Your Day”:\n\no “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\n\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\n\no “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\n\n• On the blog post “Collagen and Joint Health”:\n\no “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\n\no “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\n\nProhemia\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Prohemia product page:\n\no “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\n\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\n\no “Prohemia contains several potent antioxidants to reduce inflammation . . .”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\n\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\n\nAltitude RX\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Altitude RX product page:\n\no “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\n\no “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\n\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\n\no “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\n\no “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\n\no “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\n\no “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\n\nOn your website https:\u002F\u002Fbrlsports.com:\n\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\n\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\n\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\n\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\n\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Take Altitude RX for altitude sickness prevention…”\n\nTrimmunity\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Trimmunity product page:\n\no “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\n\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\n\no “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\n\no “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\n\no “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\n\no “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\n\no “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\n\nYour Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 612831 when replying.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –West Division 5","Biomedical Research Laboratories, LLC","biomedical-research-laboratories-llc-612831-07012021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021","2026-10-26T08:08:05.137198+00:00","2021-07-13","612831","Food & Beverages","Mr. Christopher Jacob","2026-08-20T02:58:27.948+00:00","2021-07-01",{"id":194,"raw":195,"subject":200,"body_html":201,"body_text":202,"firm_name":203,"letter_id":204,"created_at":205,"fei_number":19,"letter_url":206,"updated_at":207,"action_type":22,"case_status":23,"posted_date":208,"marcs_cms_no":209,"product_type":26,"closeout_date":19,"issuing_office":101,"recipient_name":210,"body_fetched_at":211,"delivery_method":212,"recipient_title":19,"reference_number":19,"action_taken_date":213,"medical_device_id":19,"response_letter_date":19},2384,[196,197,198,101,199,13,13,13],"\u003Ctime datetime=\"2022-10-25T13:20:00Z\">10\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-26T04:00:00Z\">09\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022\">Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Kitty Hunter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Cosmetic Research Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20550 Prairie Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chatsworth\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91311-6006\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 26, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Hunter:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> Antibacterial Acne Soap, and maintain it in a good state of repair.\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Pipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\u003C\u002Fli>\n\t\u003Cli>Numerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\u003C\u002Fli>\n\t\u003Cli>Multiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>It is essential that your facility is in a good state of repair and sanitary conditions are maintained.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Photographic evidence of any repairs made to your facilities and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\u003C\u002Fp>\n\n\u003Cp>For example, regarding your batch record for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sunscreen SPF-30 lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Finished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\u003C\u002Fli>\n\t\u003Cli>Out-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\u003C\u002Fli>\n\t\u003Cli>“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\u003C\u002Fp>\n\n\u003Cp>Furthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\u003C\u002Fp>\n\n\u003Cp>Without adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\u003Cbr>\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\u003C\u002Fp>\n\n\u003Cp>Examples of labeling claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM\u003Cbr>\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&amp;C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\u003C\u002Fp>\n\n\u003Cp>However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because \u003Cstrong>(b)(4)\u003C\u002Fstrong> 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612\u003Cbr>\n\u003Cbr>\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Ms. Celeste Guillen, CEO (via email \u003Cstrong>(b)(6)\u003C\u002Fstrong>)\u003Cbr>\nAdvanced Cosmetic Research Laboratories Inc.\u003Cbr>\n20550 Prairie Street\u003Cbr>\nChatsworth, CA 91311-6006\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Kitty Hunter\n\nRecipient Title\n\nPresident and Owner\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 26, 2022\n\nDear Ms. Hunter:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Advanced Cosmetic Research Laboratories Inc., FEI 3003059934, at 20550 Prairie Street, Chatsworth, from April 21 to 27, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, (b)(4) 5% LIDOCAINE CREAM is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nWe have not received a detailed response from your firm for corrective actions to the observations identified during the inspection in our Form FDA 483. The correspondence received included a commitment to respond on or before October 1, 2022, with more information.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state repair (21 CFR 211.58).\n\nYou failed to adequately design your facility, which is used to manufacture over-the-counter (OTC) topical drug products such as (b)(4) Antibacterial Acne Soap, and maintain it in a good state of repair.\n\nFor example:\n\nPipes with apparent rust, dirt and\u002For debris were located directly above partially open mixing tanks. Our investigators observed foreign particles floating in a mixing tank used to manufacture human drug products that was located directly underneath one of these pipes.\n\nNumerous aluminum sheet panels located on the ceiling above partially open mixing tanks and filling\u002Fpackaging lines were falling, torn or had gaps which exposed the environment below to apparent dirt and debris from plywood sheeting supporting the roof.\n\nMultiple bug zappers were observed in close proximity to filling\u002Fpackaging lines. Insects killed by the zappers could fall into open equipment and finished product packaging.\n\nIt is essential that your facility is in a good state of repair and sanitary conditions are maintained.\n\nIn response to this letter, provide:\n\nYour corrective action and preventative action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nPhotographic evidence of any repairs made to your facilities and equipment.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22(a) and (d)).\n\nYour quality unit (QU) failed to have adequate procedures, documentation and practices to properly exercise its functions.\n\nFor example, regarding your batch record for (b)(4) Sunscreen SPF-30 lot (b)(4):\n\nFinished drug “Product Analysis Report” used for batch release, was signed as reviewed and approved on March 23, 2022, even though the batch was still being filled on March 28, 2022.\n\nOut-of-specification (OOS) results for viscosity and specific gravity in bulk and finished drug product were not investigated.\n\n“LINE SET-UP” form did not have an approval signature, yet the line was used to manufacture drug product.\n\nThe procedure for handling complaints was not followed as both your firm’s CEO and Project Manager confirmed that product quality complaints are not recorded, evaluated, or investigated.\n\nFurthermore, OOS results were not being appropriately investigated per your procedure for handling OOS results and non-conforming drug product. During the inspection, our investigators were informed that your firm did not maintain a list of OOS test results and that investigations were not conducted. FDA inspected your firm’s contract testing laboratory from (b)(4), where numerous analytical OOS results involving your firm’s drug products were observed. An investigation is required whenever an OOS test result is obtained and a written record of the investigation must include conclusions and follow-up.\n\nWithout adequate quality procedures and oversight, you cannot ensure the consistency of your manufacturing processes and the purported identity, strength, quality, and purity of drug products released to the market. See FDA's guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of the CGMP regulations (21 CFR, parts 210 and 211) at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging\n\nmanufacturing\u002Fquality issues and to assure a continuing state of control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nAn assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\nUnapproved New Drug and Misbranding Violations\n\n(b)(4) 5% LIDOCAINE CREAM is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a topical external analgesic.\n\nExamples of labeling claims observed on the (b)(4) 5% LIDOCAINE CREAM product label that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“(b)(4) 5% LIDOCAINE CREAM\n\n“Lidocaine 5% . . . Uses: for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts and scrapes . . . 30g | 5% Lidocaine Cream . . .” [from your product label]\n\n(b)(4) 5% LIDOCAINE CREAM is a topical external analgesic drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&C Act, 21 U.S.C. 355h(a)(1), category I drugs that were subject to a tentative final monograph (TFM) that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 are deemed to be generally recognized as safe and effective (GRASE) and not “new drugs,” as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements. We note that over-the-counter (OTC) topical external analgesic products were addressed in the TFM for External Analgesic Drug Products for Over-the-Counter Human Use (external analgesic TFM; 48 FR 5852, February 8, 1983) and subsequent rulemakings. Under 505G(b)(8) of the FD&C Act, the 1983 external analgesic TFM, in combination with subsequent rulemakings, was deemed to be a final administrative order.\n\nHowever, (b)(4) 5% LIDOCAINE CREAM does not conform to the conditions of use specified in the final administrative order. Specifically, the labeled active ingredient in the product, Lidocaine 5%, is above the allowable dosage concentration for use as an over-the-counter external analgesic product (0.5 – 4%).\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that (b)(4) 5% LIDOCAINE CREAM is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section and 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because (b)(4) 5% LIDOCAINE CREAM is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to unique identifier CMS 631902 and be sent electronically to ORAPHARM4_Responses@fda.hhs.gov or mailed to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612\n\nIf you have any questions regarding this letter, please contact Jamie Dion, compliance officer, at 303-236-3133 or by email at Jamie.Dion@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCC: Ms. Celeste Guillen, CEO (via email (b)(6))\n\nAdvanced Cosmetic Research Laboratories Inc.\n\n20550 Prairie Street\n\nChatsworth, CA 91311-6006","Advanced Cosmetic Research Laboratories Inc.","advanced-cosmetic-research-laboratories-inc-635176-09262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-cosmetic-research-laboratories-inc-635176-09262022","2026-10-26T08:07:50.485867+00:00","2022-10-25","635176","Ms. Kitty Hunter","2026-08-20T01:29:18.013+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-09-26",{"id":215,"raw":216,"subject":159,"body_html":220,"body_text":221,"firm_name":222,"letter_id":223,"created_at":224,"fei_number":19,"letter_url":225,"updated_at":226,"action_type":22,"case_status":23,"posted_date":227,"marcs_cms_no":228,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":229,"body_fetched_at":230,"delivery_method":170,"recipient_title":19,"reference_number":19,"action_taken_date":231,"medical_device_id":19,"response_letter_date":19},21674,[217,218,219,11,159,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026\">Lovelace Biomedical Research Institute\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert W. Rubin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lovelace Biomedical Research Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2425 Ridgecrest Drive SE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 27-HFD-45-10-01\u003C\u002Fp>\u003Cp>Dear Mr. Rubin:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations found in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\u003C\u002Fp>\u003Cp>2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\u003C\u002Fp>\u003Cp>b. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\u003C\u002Fp>\u003Cp>c. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\u003C\u002Fp>\u003Cp>d. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following concerns and observations noted in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\u003C\u002Fp>\u003Cp>4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\u003C\u002Fp>\u003Cp>b. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\u003C\u002Fp>\u003Cp>c. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\u003C\u002Fp>\u003Cp>d. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\u003C\u002Fp>\u003Cp>We acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\u003C\u002Fp>\u003Cp>In your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>10\u002F06\u002F2026 10:05:58 AM\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert W. Rubin\n\nRecipient Title\n\nCEO\n\nLovelace Biomedical Research Institute\n\n2425 Ridgecrest Drive SE\n\nAlbuquerque, NM 87108\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 27-HFD-45-10-01\nDear Mr. Rubin:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\nFailure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\nSpecifically, for Protocol (b)(4), the following observations found in the raw data were not documented in the final study report:\n1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\n2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\na. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\nb. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\nc. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\nd. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\nSpecifically, for Protocol (b)(4), the following concerns and observations noted in the raw data were not documented in the final study report:\n3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\n4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\na. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\nb. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\nc. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\nd. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\nWe acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\nIn your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols (b)(4) and (b)(4) by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n10\u002F06\u002F2026 10:05:58 AM","Lovelace Biomedical Research Institute","lovelace-biomedical-research-institute-725136-10062026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-13","725136","Robert W. Rubin","2026-10-14T12:32:02.221+00:00","2026-10-06",{"id":233,"raw":234,"subject":238,"body_html":239,"body_text":240,"firm_name":241,"letter_id":242,"created_at":86,"fei_number":19,"letter_url":243,"updated_at":244,"action_type":22,"case_status":23,"posted_date":245,"marcs_cms_no":246,"product_type":26,"closeout_date":19,"issuing_office":157,"recipient_name":247,"body_fetched_at":248,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":249,"medical_device_id":19,"response_letter_date":19},1509,[235,236,237,157,238,13,13,13],"\u003Ctime datetime=\"2024-04-23T13:20:00Z\">04\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-18T04:00:00Z\">04\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024\">Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.\u003C\u002Fa>","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Samantha Ross\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11 East Park Road Shenoy Nagar\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chennai\u003C\u002Fspan> \u003Cspan>600030\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:registration@fdaimports.com\"> registration@fdaimports.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 18, 2024\u003Cbr>\n\u003Cbr>\nRE: WL 2643\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Ross:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm NDC, 70146-010; Womens Sports Balm, NDC 70146-011and Hand Sanitizer NDC 70146-012.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the previously mentioned drugs, the manufacturer referenced is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided December 15, 2022, to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not involved in manufacturing of the drugs mentioned above, and therefore, this firm should not be registered with FDA as a manufacturer. On March 6, 2023, OQS\u002FOPQ requested that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. deregister their establishment and delist all drug listings which reference Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. as the manufacturer. However, to date, no updates have been made to the listing files to correct the manufacturer’s name and the firm remains registered as a manufacturer. In addition, many of the listings mentioned above include other listing errors such as an incorrect dosage form, mismatched strength of an active ingredient, missing active ingredient, and incorrect label images. Therefore, these products are in violation of the following additional regulations under section 510(j)(1)(c) and 21 CFR 207.49(a)(6), 21 CFR 207.49 (a)(4) and 21 CFR 207.49(a)(15)(ii)(B). The table below includes products with associated listing errors.\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>NDC\u003C\u002Ftd>\n\t\t\t\u003Ctd>Proprietary Name\u003C\u002Ftd>\n\t\t\t\u003Ctd>Error(s) Found\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-000\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003Cbr>\n\t\t\t3.The labeling also includes a carton label image of another product which is not listed.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-001\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of the listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-002\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-003\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. Mismatched strength of menthol in the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-004\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-005\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm,\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-006\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-007\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. The listing SPL does not include the active ingredient methyl salicylate which is found in the labeling.\u003Cbr>\n\t\t\t3. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-008\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-009\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-010\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Relief Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-011\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Womens Sports Balm\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003Cbr>\n\t\t\t2. There is a mismatched dosage form between the labeling and the listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>70146-012\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>Hand Sanitizer\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>1. Incorrect manufacturer included under the establishment section of listing SPL.\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm, NDC 70146-010; Womens Sports Balm, NDC 70146-011; and Hand Sanitizer NDC 70146-012 are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products included in the table above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2643 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSamantha Ross\n\nDr Sankunni’s Ayurvedic Research Foundation Private Ltd.\n\n11 East Park Road Shenoy Nagar\n\nChennai 600030\n\nTamil Nadu\n\nIndia\n\nregistration@fdaimports.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nApril 18, 2024\n\nRE: WL 2643\n\nDear Ms. Ross:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for the following drug products: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm NDC, 70146-010; Womens Sports Balm, NDC 70146-011and Hand Sanitizer NDC 70146-012.1 Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for the previously mentioned drugs, the manufacturer referenced is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided December 15, 2022, to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not involved in manufacturing of the drugs mentioned above, and therefore, this firm should not be registered with FDA as a manufacturer. On March 6, 2023, OQS\u002FOPQ requested that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. deregister their establishment and delist all drug listings which reference Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. as the manufacturer. However, to date, no updates have been made to the listing files to correct the manufacturer’s name and the firm remains registered as a manufacturer. In addition, many of the listings mentioned above include other listing errors such as an incorrect dosage form, mismatched strength of an active ingredient, missing active ingredient, and incorrect label images. Therefore, these products are in violation of the following additional regulations under section 510(j)(1)(c) and 21 CFR 207.49(a)(6), 21 CFR 207.49 (a)(4) and 21 CFR 207.49(a)(15)(ii)(B). The table below includes products with associated listing errors.\n\nNDC\nProprietary Name\nError(s) Found\n\n70146-000\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n3.The labeling also includes a carton label image of another product which is not listed.\n\n70146-001\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of the listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-002\n\nSports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-003\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. Mismatched strength of menthol in the listing SPL.\n\n70146-004\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-005\n\nSports Balm,\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-006\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n70146-007\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. The listing SPL does not include the active ingredient methyl salicylate which is found in the labeling.\n\n3. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-008\n\nRelief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-009\n\nSports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-010\n\nWomens Relief Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-011\n\nWomens Sports Balm\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\n2. There is a mismatched dosage form between the labeling and the listing SPL.\n\n70146-012\n\nHand Sanitizer\n\n1. Incorrect manufacturer included under the establishment section of listing SPL.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs: Relief Balm, NDC 70146-000; Womens Relief Balm, NDC 70146-001; Sports Balm, NDC 70146-002; Womens Sports Balm, NDC 70146-003; Relief Balm, NDC 70146-004; Sports Balm, NDC 70146-005; Womens Relief Balm, NDC 70146-006; Womens Sports Balm, NDC 70146-007; Relief Balm, NDC 70146-008; Sports Balm, NDC 70146-009; Womens Relief Balm, NDC 70146-010; Womens Sports Balm, NDC 70146-011; and Hand Sanitizer NDC 70146-012 are not properly listed with FDA causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products included in the table above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2643 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________________\n\n1 On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Dr Sankunni’s Ayurvedic Research Foundation Private Ltd.","dr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdr-sankunnis-ayurvedic-research-foundation-private-ltd-678046-04182024","2026-10-26T08:08:26.88063+00:00","2024-04-23","678046","Samantha Ross","2026-08-20T00:09:54.678+00:00","2024-04-18",{"id":251,"raw":252,"subject":256,"body_html":257,"body_text":258,"firm_name":259,"letter_id":260,"created_at":261,"fei_number":19,"letter_url":262,"updated_at":263,"action_type":22,"case_status":23,"posted_date":264,"marcs_cms_no":265,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":266,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":267,"medical_device_id":19,"response_letter_date":19},390,[253,254,255,11,256,13,13,13],"\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpinnacle-professional-research-dba-pinnacle-peptides-719337-12122025\">Pinnacle Professional Research dba Pinnacle Peptides\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pinnacle Professional Research dba Pinnacle Peptides\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 N Elm Street, Suite 31\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greensboro\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27401\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:service@pinnaclepeptides.com\"> service@pinnaclepeptides.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>RE: 719337\u003C\u002Fp>\u003Cp>Pinnacle Professional Research dba Pinnacle Peptides:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.pinnaclepeptides.com in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “SARM’s S4 ANDARINE,” “LGD-4033,” and “MK-2866” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>FDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Despite statements on your product labeling marketing your products, “FOR RESEARCH ONLY” and “NOT FOR HUMAN USE,” evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>SARM's S4 ANDARINE\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-s4-sarms.html:\u003C\u002Fp>\u003Cul>\u003Cli>“Andarine . . . is a non-steroidal selective androgen receptor modulator (SARM) . . . anabolic activity is similar to that of testosterone’s . . . for musculoskeletal disorders and benign prostatic hyperplasia [and] found to improve fertility and sexual health in men and women.”\u003C\u002Fli>\u003Cli>“Cancer . . . Andarine might have the ability to inhibit tumor growth. The androgen receptor has been shown to be associated with the development of pancreatic cancer. Hence, SARMs might prove effective in treating pancreatic cancer.”\u003C\u002Fli>\u003Cli>“[A]ndarine shows anticarcinogenic effects on lung cancer by inhibiting cell growth and proliferation and promoting apoptosis.”\u003C\u002Fli>\u003Cli>“Literature supports the evidence that S4 can boost muscle mass and increase strength.”\u003C\u002Fli>\u003Cli>“Andarine positively impacts bone mineral density and might offer a promising treatment for osteoporosis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>LGD-4033\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-lgd-4033.html:\u003C\u002Fp>\u003Cul>\u003Cli>“LGD-4033 . . . belongs to the class selective androgen receptor modulator (SARM). . . . [I]t exerts anabolic effects on muscles and bones without causing side effects associated with steroids.”\u003C\u002Fli>\u003Cli>“Osteoporosis . . . Ligandrol binds to the androgen receptors in bone cells and stimulates the activity of osteoblasts. Osteoblasts are the bone cells mainly responsible for the formation of bone and mineral deposition.”\u003C\u002Fli>\u003Cli>“Hormonal decline with age is associated with the loss of muscle health and function. . . . [L]igandrol can counteract these changes and boost muscle strength and mass.”\u003C\u002Fli>\u003Cli>“As ligandrol has been shown to improve bone mineral density, it might also speed up the healing of fractured bones.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>MK-2866\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-mk2866.html:\u003C\u002Fp>\u003Cul>\u003Cli>“MK-2866 . . . belongs to the class selective androgen receptor modulator (SARM). . . . [I]t increases muscle mass and growth, improves insulin sensitivity and prevents bone loss. It has also been shown to treat breast cancer.”\u003C\u002Fli>\u003Cli>“[MK-2866] binds with androgen receptors in specific tissues such as muscles. This triggers the cascade of intracellular signaling, resulting in protein synthesis within muscle cells that promotes muscle growth and repair.”\u003C\u002Fli>\u003Cli>“One study investigated the effect of ostarine on cachexia in cancer patients. . . . [R]esults indicated a significant increase in lean body mass in patients who took ostarine as compared to the control group.”\u003C\u002Fli>\u003Cli>“Insulin Sensitivity . . . antidiabetic effect”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products marketed as SARMs are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719337” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPinnacle Professional Research dba Pinnacle Peptides\n\n1001 N Elm Street, Suite 31\n\nGreensboro, NC 27401\n\nUnited States\n\nservice@pinnaclepeptides.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nDecember 12, 2025\nRE: 719337\nPinnacle Professional Research dba Pinnacle Peptides:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.pinnaclepeptides.com in November 2025. The FDA has observed that you offer products marketed on your firm’s website as selective androgen receptor modulators (SARMs) including, but not limited to, “SARM’s S4 ANDARINE,” “LGD-4033,” and “MK-2866” (hereinafter products marketed as SARMs) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nFDA has safety concerns about products that contain SARMs. Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs. SARMs also have the potential to increase the risk of heart attack and stroke.1\nDespite statements on your product labeling marketing your products, “FOR RESEARCH ONLY” and “NOT FOR HUMAN USE,” evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use. Based on a review of your website, your products marketed as SARMs are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nSARM's S4 ANDARINE\nOn the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-s4-sarms.html:\n“Andarine . . . is a non-steroidal selective androgen receptor modulator (SARM) . . . anabolic activity is similar to that of testosterone’s . . . for musculoskeletal disorders and benign prostatic hyperplasia [and] found to improve fertility and sexual health in men and women.”\n“Cancer . . . Andarine might have the ability to inhibit tumor growth. The androgen receptor has been shown to be associated with the development of pancreatic cancer. Hence, SARMs might prove effective in treating pancreatic cancer.”\n“[A]ndarine shows anticarcinogenic effects on lung cancer by inhibiting cell growth and proliferation and promoting apoptosis.”\n“Literature supports the evidence that S4 can boost muscle mass and increase strength.”\n“Andarine positively impacts bone mineral density and might offer a promising treatment for osteoporosis.”\nLGD-4033\nOn the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-lgd-4033.html:\n“LGD-4033 . . . belongs to the class selective androgen receptor modulator (SARM). . . . [I]t exerts anabolic effects on muscles and bones without causing side effects associated with steroids.”\n“Osteoporosis . . . Ligandrol binds to the androgen receptors in bone cells and stimulates the activity of osteoblasts. Osteoblasts are the bone cells mainly responsible for the formation of bone and mineral deposition.”\n“Hormonal decline with age is associated with the loss of muscle health and function. . . . [L]igandrol can counteract these changes and boost muscle strength and mass.”\n“As ligandrol has been shown to improve bone mineral density, it might also speed up the healing of fractured bones.”\nMK-2866\nOn the webpage https:\u002F\u002Fwww.pinnaclepeptides.com\u002Fbuy-mk2866.html:\n“MK-2866 . . . belongs to the class selective androgen receptor modulator (SARM). . . . [I]t increases muscle mass and growth, improves insulin sensitivity and prevents bone loss. It has also been shown to treat breast cancer.”\n“[MK-2866] binds with androgen receptors in specific tissues such as muscles. This triggers the cascade of intracellular signaling, resulting in protein synthesis within muscle cells that promotes muscle growth and repair.”\n“One study investigated the effect of ostarine on cachexia in cancer patients. . . . [R]esults indicated a significant increase in lean body mass in patients who took ostarine as compared to the control group.”\n“Insulin Sensitivity . . . antidiabetic effect”\nYour products marketed as SARMs are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “719337” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n__________________\n1 See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002Ffda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults.","Pinnacle Professional Research dba Pinnacle Peptides","pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpinnacle-professional-research-dba-pinnacle-peptides-719337-12122025","2026-10-26T08:09:42.231204+00:00","2025-12-23","719337","2026-08-19T07:20:12.662+00:00","2025-12-12",{"id":269,"raw":270,"subject":159,"body_html":274,"body_text":275,"firm_name":276,"letter_id":277,"created_at":261,"fei_number":19,"letter_url":278,"updated_at":279,"action_type":22,"case_status":23,"posted_date":280,"marcs_cms_no":281,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":282,"body_fetched_at":283,"delivery_method":170,"recipient_title":19,"reference_number":284,"action_taken_date":285,"medical_device_id":19,"response_letter_date":19},131,[271,272,273,11,159,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026\">HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-05-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leah R. Hanson, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Neuroscience Research\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>295 Phalen Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55130-2455\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-05-02\u003C\u002Fp>\u003Cp>Dear Dr. Hanson:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for sponsor-investigator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (formerly performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, the protocol and final study report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated that the test article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4) \u003C\u002Fstrong>(0.5 mg, 5 mg, and 10 mg, respectively), and for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot used in study \u003Cstrong>(b)(4)\u003C\u002Fstrong>; (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.&nbsp;\u003C\u002Fp>\u003Cp>In addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Your testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations were not accurately documented in the final study report:\u003C\u002Fp>\u003Cp>a. The deaths of two male rats (Rats #41 and #42 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group) during the conduct of the study were not reflected in the final study report.\u003C\u002Fp>\u003Cp>b. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group.\u003C\u002Fp>\u003Cp>c. Female Rat #84 in the 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Testing facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, during the conduct of nonclinical laboratory studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\u003C\u002Fp>\u003Cul>\u003Cli>Hematology test results for male and female rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Serum chemistry test results for male rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hematology test results for male and female rabbits for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> or rabbit blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\u003C\u002Fp>\u003Cp>a. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\u003C\u002Fp>\u003Cp>b. Test system observations\u003C\u002Fp>\u003Cp>c. Laboratory tests\u003C\u002Fp>\u003Cp>d. Handling of animals found to be moribund or dead during a study\u003C\u002Fp>\u003Cp>e. Collection and identification of specimens\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs \u003Cem>before\u003C\u002Fem> conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\u003C\u002Fp>\u003Cp>As evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>05\u002F19\u002F2026 12:58:47 PM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-05-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeah R. Hanson, Ph.D.\n\nRecipient Title\n\nSenior Director, Neuroscience Research\n\nHealthPartners Neuroscience Center Research and Innovation\n\n295 Phalen Boulevard\n\nSaint Paul, MN 55130-2455\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-05-02\nDear Dr. Hanson:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug (b)(4), performed for sponsor-investigator (b)(4) (formerly performed for (b)(4)).\nProtocol (b)(4): “(b)(4)”\nProtocol (b)(4): “(b)(4)”\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\n1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\nThe testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\nSpecifically, the protocol and final study report for Study (b)(4) stated that the test article, (b)(4), was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% (b)(4) (0.5 mg, 5 mg, and 10 mg, respectively), and for Study (b)(4), to a final dose concentration of 1%, 10%, or 20% (b)(4) (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies (b)(4) and (b)(4).\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the (b)(4) lot used in study (b)(4); (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.\nIn addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\nYour testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\n2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol (b)(4), the following observations were not accurately documented in the final study report:\na. The deaths of two male rats (Rats #41 and #42 in the 10% (b)(4) dosing group) during the conduct of the study were not reflected in the final study report.\nb. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% (b)(4) dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% (b)(4) dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% (b)(4) dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% (b)(4) dosing group.\nc. Female Rat #84 in the 20% (b)(4) dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\nIn your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\nTesting facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\nSpecifically, during the conduct of nonclinical laboratory studies (b)(4) and (b)(4), the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\nHematology test results for male and female rats for Protocol (b)(4)\nSerum chemistry test results for male rats for Protocol (b)(4)\nHematology test results for male and female rabbits for Protocol (b)(4)\nAdditionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol (b)(4) or rabbit blood in Protocol (b)(4).\nWe acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol (b)(4). Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\nIn your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\nWhile we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\nA testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\na. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\nb. Test system observations\nc. Laboratory tests\nd. Handling of animals found to be moribund or dead during a study\ne. Collection and identification of specimens\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs before conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\nAs evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n05\u002F19\u002F2026 12:58:47 PM","HealthPartners Neuroscience Center Research and Innovation","healthpartners-neuroscience-center-research-and-innovation-725333-05192026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-10-26T08:08:53.733946+00:00","2026-06-02","725333","Leah R. Hanson, Ph.D.","2026-08-19T04:39:07.121+00:00","26-HFD-45-05-02","2026-05-19",{"id":287,"raw":288,"subject":39,"body_html":292,"body_text":293,"firm_name":294,"letter_id":295,"created_at":86,"fei_number":19,"letter_url":296,"updated_at":297,"action_type":22,"case_status":23,"posted_date":298,"marcs_cms_no":299,"product_type":26,"closeout_date":19,"issuing_office":157,"recipient_name":300,"body_fetched_at":301,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":302,"medical_device_id":19,"response_letter_date":19},1566,[289,290,291,157,39,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-08T05:00:00Z\">03\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspirochaete-research-labs-llc-aka-scitus-laboratory-products-674278-03082024\">Spirochaete Research Labs, LLC aka Scitus Laboratory Products\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eric C. Ritter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Spirochaete Research Labs, LLC aka Scitus Laboratory Products\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>822 Terry Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hauppauge\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11788\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:eric.ritter@spirochaetelabs.com\"> eric.ritter@spirochaetelabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 8, 2024\u003Cbr>\n\u003Cbr>\nRE: 3023254292\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ritter:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of over-the-counter (OTC) stimulant drug products. “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as stimulant drug products.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on the products’ labeling, including your product labels, product website (https:\u002F\u002Fatomicrhino.com\u002F), where products are available for purchase, and social media websites, such as Instagram, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“…DESIGNED WITH PROFESSIONAL ATHLETES IN MIND - Atomic Rhino ammonia smelling salts are perfect for giving you that extra boost while lifting and powerlifting but also ideal for athletes involved in high intensity sports like hockey, football, and basketball, where the fast adrenaline rush action can sometimes result in injuries or exhaustion…” [from your website under Buy Now\u002FOriginal Smelling Salts\u002FDescription\u003Cbr>\nhttps:\u002F\u002Fatomicrhino.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“EXPLOSIVE ENERGY AND FOCUS\u003Cbr>\nMassive Boost in psychological athleticism, get the grip you need to excel.”\u003Cbr>\n[from your website under Buy Now\u002FOriginal Smelling Salts https:\u002F\u002Fatomicrhino.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“BENEFITS YOU CAN FEEL\u003Cbr>\nMAXIMUM STRENGTH EXPLOSIVE ENERGY RAZOR-SHARP FOCUS”\u003Cbr>\n[from your website under Buy Now\u002FOriginal Smelling Salts https:\u002F\u002Fatomicrhino.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“I needed something to help me make it through the afternoons work. I was skeptical but I didn’t want to put more caffeine in my diet. This product really works and helps wake me up when tired.” [from your website under Buy Now\u002FRed Line https:\u002F\u002Fatomicrhino.com\u002F]\u003C\u002Fp>\n\n\u003Cp>“These smelling salts are very very strong and will ensure you get the big rep you need and even another one due to the product lasting once you use it.” [from a post on your Instagram webpage, dated 12\u002F23\u002F2020, at https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmiaaYoModq\u002F]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” drug products, containing the ingredients ammonium chloride, ammonium hydroxide, sodium polyacrylate and\u002For sodium carbonate are intended for use as stimulant drug products. Specifically, these products are intended for use as both reflex stimulants (i.e., smelling salts, ammonia inhalants) and, more generally, as stimulants to help restore mental alertness or wakefulness. As described below, these stimulant drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the four products identified above.\u003C\u002Fp>\n\n\u003Cp>“ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are reflex stimulant drug products subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these reflex stimulant drug products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> On June 19, 2008, FDA issued a proposed rule (73 FR 34895)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008, proposed rule is the most recent applicable FDA proposal issued under 21 CFR part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, these reflex stimulant drug products are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Even if “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” were not marketed as reflex stimulant drug products and were only marketed as more general stimulant drug products, your products would still not meet the requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, stimulant drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” stimulant drug products do not conform to the conditions of use specified in Monograph M011 because your products are formulated with the active ingredients, ammonium hydroxide or ammonium chloride,\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and are labeled with directions for intranasal administration, neither of which are covered under the deemed final order. Therefore, even if your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” were marketed as only general stimulant drug products, they would not meet requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Lastly, “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) or are misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330 prior to enactment of the CARES Act. In the case of OTC stimulant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nEric C. Ritter\n\nSpirochaete Research Labs, LLC aka Scitus Laboratory Products\n\n822 Terry Rd.\n\nHauppauge, NY 11788\n\nUnited States\n\neric.ritter@spirochaetelabs.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nMarch 8, 2024\n\nRE: 3023254292\n\nDear Mr. Ritter:\n\nThis letter concerns your firm’s distribution of over-the-counter (OTC) stimulant drug products. “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\n“ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as stimulant drug products.\n\nExamples of the claims observed on the products’ labeling, including your product labels, product website (https:\u002F\u002Fatomicrhino.com\u002F), where products are available for purchase, and social media websites, such as Instagram, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n“…DESIGNED WITH PROFESSIONAL ATHLETES IN MIND - Atomic Rhino ammonia smelling salts are perfect for giving you that extra boost while lifting and powerlifting but also ideal for athletes involved in high intensity sports like hockey, football, and basketball, where the fast adrenaline rush action can sometimes result in injuries or exhaustion…” [from your website under Buy Now\u002FOriginal Smelling Salts\u002FDescription\n\nhttps:\u002F\u002Fatomicrhino.com\u002F]\n\n“EXPLOSIVE ENERGY AND FOCUS\n\nMassive Boost in psychological athleticism, get the grip you need to excel.”\n\n[from your website under Buy Now\u002FOriginal Smelling Salts https:\u002F\u002Fatomicrhino.com\u002F]\n\n“BENEFITS YOU CAN FEEL\n\nMAXIMUM STRENGTH EXPLOSIVE ENERGY RAZOR-SHARP FOCUS”\n\n[from your website under Buy Now\u002FOriginal Smelling Salts https:\u002F\u002Fatomicrhino.com\u002F]\n\n“I needed something to help me make it through the afternoons work. I was skeptical but I didn’t want to put more caffeine in my diet. This product really works and helps wake me up when tired.” [from your website under Buy Now\u002FRed Line https:\u002F\u002Fatomicrhino.com\u002F]\n\n“These smelling salts are very very strong and will ensure you get the big rep you need and even another one due to the product lasting once you use it.” [from a post on your Instagram webpage, dated 12\u002F23\u002F2020, at https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCmiaaYoModq\u002F]\n\nBased on the above labeling claims, your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” drug products, containing the ingredients ammonium chloride, ammonium hydroxide, sodium polyacrylate and\u002For sodium carbonate are intended for use as stimulant drug products. Specifically, these products are intended for use as both reflex stimulants (i.e., smelling salts, ammonia inhalants) and, more generally, as stimulants to help restore mental alertness or wakefulness. As described below, these stimulant drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the four products identified above.\n\n“ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are reflex stimulant drug products subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these reflex stimulant drug products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), because they are subject to a determination to be not GRASE in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330. The term “smelling salt” typically is used to refer to an ammonia aromatic preparation used as a reflex stimulant.1 On June 19, 2008, FDA issued a proposed rule (73 FR 34895)2 setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not GRASE or are misbranded. This June 19, 2008, proposed rule is the most recent applicable FDA proposal issued under 21 CFR part 330 with respect to ammonia as a reflex stimulant in OTC drug products. Thus, these reflex stimulant drug products are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.3\n\nEven if “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” were not marketed as reflex stimulant drug products and were only marketed as more general stimulant drug products, your products would still not meet the requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\n\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, stimulant drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph, M011: Stimulant Drug Products for Over-the-Counter Human Use (hereinafter M011).4 However, your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” stimulant drug products do not conform to the conditions of use specified in Monograph M011 because your products are formulated with the active ingredients, ammonium hydroxide or ammonium chloride,5 and are labeled with directions for intranasal administration, neither of which are covered under the deemed final order. Therefore, even if your “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” were marketed as only general stimulant drug products, they would not meet requirements under section 505G, under which they would be deemed to be GRASE and not a new drug.\n\nIn addition, the FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling. Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nLastly, “ATOMIC RHINO -(SMELLING SALTS)-,” “RED LINE ATOMIC RHINO -(SMELLING SALTS)-,” “MEGATON ATOMIC RHINO -(SMELLING SALTS)-,” and “MEGATON RED LINE ATOMIC RHINO -(SMELLING SALTS)-” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________\n\n1 Merriam Webster’s dictionary defines “smelling salts” as “a usually scented aromatic preparation of ammonium carbonate and ammonia water used as a stimulant and restorative.”\n\n2 On June 19, 2008, FDA issued a proposed rule (73 FR 34895) setting forth a determination that ammonia and any other ammonia ingredient in a drug product that is labeled with claims or directions for use as a reflex stimulant are not generally recognized as safe and effective (GRASE) or are misbranded.\n\n3 FDA did not determine that it was in the interest of public health to extend the period during which any drug subject to section 505G(a)(4) may be marketed without an approved new drug application.\n\n4 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 C.F.R. part 330 prior to enactment of the CARES Act. In the case of OTC stimulant drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M011: Stimulant Drug Products for Over-the-Counter Human Use. (Over-the-Counter Monograph M011 Final Administrative Order (OTC000025)\n\n5 M011 specifies that caffeine, in a form suitable for oral administration, is the only acceptable active ingredient for use as a stimulant under the order.","Spirochaete Research Labs, LLC aka Scitus Laboratory Products","spirochaete-research-labs-llc-aka-scitus-laboratory-products-674278-03082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspirochaete-research-labs-llc-aka-scitus-laboratory-products-674278-03082024","2026-10-26T08:10:02.957106+00:00","2024-03-12","674278","Eric C. Ritter","2026-08-20T00:14:46.252+00:00","2024-03-08",{"id":304,"raw":305,"subject":309,"body_html":310,"body_text":311,"firm_name":312,"letter_id":313,"created_at":261,"fei_number":19,"letter_url":314,"updated_at":315,"action_type":22,"case_status":23,"posted_date":316,"marcs_cms_no":317,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":318,"body_fetched_at":319,"delivery_method":170,"recipient_title":19,"reference_number":320,"action_taken_date":321,"medical_device_id":19,"response_letter_date":19},179,[306,307,308,11,309,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-29T04:00:00Z\">04\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026\">Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital &amp; Research Centre \u003C\u002Fa>","In Vivo Bioavailability-Bioequivalence Studies – Clinical","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-04-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mukesh B. Chandre, M.D., MBBS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital &amp; Research Centre \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Maratha Section, Near Jijamata Udhyan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ulhasnagar\u003C\u002Fspan> \u003Cspan>421004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Maharashtra\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-04-01\u003C\u002Fp>\u003Cp>Dear Dr. Chandre:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Ashirwad Hospital &amp; Research Centre in Ulhasnagar, Maharashtra, India, between May 5 and May 9, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm\u003Csup>2\u003C\u002Fsup> dose) (Doxorubicin- Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 28, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 28, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\u003C\u002Fp>\u003Cp>You failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\u003C\u002Fp>\u003Cp>In your May 28, 2025, written response to the Form FDA 483, you stated that the word “study drug” should have been described as “approved study drug”. You also stated that the Ethics Committee approved the ICF, you complied with all other requirements for the ICF, the ICF adequately described the risk of the test product in other sections, and you, as the clinical investigator, had consent discussions with trial participants that clarified the experimental nature, the associated risk, and that there is no guaranteed benefit of the test drug.\u003C\u002Fp>\u003Cp>In addition, you stated that the CRO revised the global ICF template to improve the description of the study drugs and to improve the section describing the study drug benefits. You also stated that your site has taken the following corrective and preventive actions, including: (1) reviewed consent forms of ongoing studies; (2) notified the ethics committee of the inspectional observations; (3) revised the site’s SOP on the informed consent process to include a provision for the investigator or qualified staff to review the content of the informed consent document for compliance with regulatory requirements; and (4) trained site personnel on the revised SOP and regulatory guidance\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your site has taken, your written response is inadequate because you did not provide sufficient details about how you, as the clinical investigator, will ensure adequate compliance with the informed consent regulations at 21 CFR part 50. Without this information, we are unable to determine whether your corrective actions appear adequate to prevent similar violations in future clinical investigations.\u003C\u002Fp>\u003Cp>We emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, including obtaining legal effective informed consent from subjects before their enrollment. Your failure to obtain informed consent in accordance with 21 CFR part 50 before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>David Burrow Digitally signed by David Burrow\u003Cbr>Date: 4\u002F29\u002F2026 12:30:34 PM EDT\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-04-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMukesh B. Chandre, M.D., MBBS\n\nMukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital & Research Centre\n\nMaratha Section, Near Jijamata Udhyan\n\nUlhasnagar 421004\n\nMaharashtra\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-04-01\nDear Dr. Chandre:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Ashirwad Hospital & Research Centre in Ulhasnagar, Maharashtra, India, between May 5 and May 9, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol 0270-22, “A Multicenter, Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study between two formulations of Doxorubicin Hydrochloride Liposome Injection 20 mg\u002F10 mL (50 mg\u002Fm2 dose) (Doxorubicin- Test compared with Doxorubicin-Reference) in Patients with Advanced Ovarian Cancer”) of the investigational product doxorubicin hydrochloride liposome injection 20 mg\u002F10 mL, performed for Qilu Pharmaceutical (Hainan) Co., Ltd.\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 28, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 28, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects.1 We wish to emphasize the following:\nYou failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].\nAs a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24,2 no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek…[informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence”.\nYou failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospective subject or the representative sufficient opportunity or information to consider whether or not to participate and that minimized the possibility of undue influence. Specifically, Section 1 of the informed consent form (ICF) stated that all reference to the words “study drug” throughout the ICF can mean Doxorubicin-Test and Doxorubicin-Reference. Section 10 of the ICF stated, “There is evidence that this study drug is effective and indicated in your disease condition.” In addition, Section 4 stated that liposomal doxorubicin is already approved by various regulatory authorities to treat the disease condition. Sections 4 and 10 also did not specify whether “liposomal doxorubicin” or “study drug”, and the statements concerning their approval or effectiveness, respectively, were applicable to the reference product or the test product. The lack of clarity may lead individuals to mistaken conclusions about the investigational product and whether it had already been demonstrated to be effective. Further, statements that overstate the possible benefit of the investigational product may unduly influence individuals to agree to participate when they might not otherwise do so.\nIn your May 28, 2025, written response to the Form FDA 483, you stated that the word “study drug” should have been described as “approved study drug”. You also stated that the Ethics Committee approved the ICF, you complied with all other requirements for the ICF, the ICF adequately described the risk of the test product in other sections, and you, as the clinical investigator, had consent discussions with trial participants that clarified the experimental nature, the associated risk, and that there is no guaranteed benefit of the test drug.\nIn addition, you stated that the CRO revised the global ICF template to improve the description of the study drugs and to improve the section describing the study drug benefits. You also stated that your site has taken the following corrective and preventive actions, including: (1) reviewed consent forms of ongoing studies; (2) notified the ethics committee of the inspectional observations; (3) revised the site’s SOP on the informed consent process to include a provision for the investigator or qualified staff to review the content of the informed consent document for compliance with regulatory requirements; and (4) trained site personnel on the revised SOP and regulatory guidance\nWhile we acknowledge the corrective and preventive actions that your site has taken, your written response is inadequate because you did not provide sufficient details about how you, as the clinical investigator, will ensure adequate compliance with the informed consent regulations at 21 CFR part 50. Without this information, we are unable to determine whether your corrective actions appear adequate to prevent similar violations in future clinical investigations.\nWe emphasize that as the clinical investigator, you are ultimately responsible for compliance with all applicable FDA regulations governing the conduct of clinical investigations and the protection of human subjects, including obtaining legal effective informed consent from subjects before their enrollment. Your failure to obtain informed consent in accordance with 21 CFR part 50 before involving subjects in research jeopardizes the rights, safety, and welfare of subjects and raises concerns about whether subjects had an adequate opportunity to fully assess the risks and benefits of their participation in the clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational product. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely yours,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nDavid Burrow Digitally signed by David Burrow\nDate: 4\u002F29\u002F2026 12:30:34 PM EDT\n______________________\n1 In accordance with 21 CFR 320.31(c), the provisions of 21 CFR parts 312 and 50 are applicable to this bioequivalence study in humans because Protocol 0270-22 was conducted under an Investigational New Drug application (IND).\n2 The exceptions provided in 21 CFR 50.22, 50.23, and 50.24 are not applicable here.","Mukesh B. Chandre, M.D., MBBS\u002FAshirwad Hospital & Research Centre","mukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmukesh-b-chandre-md-mbbsashirwad-hospital-research-centre-724911-04292026","2026-10-26T08:09:28.594998+00:00","2026-05-12","724911","Mukesh B. Chandre, M.D., MBBS","2026-08-19T04:42:53.526+00:00","26-HFD-45-04-01","2026-04-29",{"id":323,"raw":324,"subject":328,"body_html":329,"body_text":330,"firm_name":331,"letter_id":332,"created_at":333,"fei_number":19,"letter_url":334,"updated_at":226,"action_type":22,"case_status":23,"posted_date":335,"marcs_cms_no":336,"product_type":337,"closeout_date":19,"issuing_office":11,"recipient_name":338,"body_fetched_at":339,"delivery_method":340,"recipient_title":19,"reference_number":19,"action_taken_date":341,"medical_device_id":19,"response_letter_date":19},22112,[325,326,327,11,328,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026\">Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yun Ma\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Product Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 3 Yiheng Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanling Gongye Districtqinghu Ma Tian Street Jiahe Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baiyun Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>510000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 27, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-13\u003C\u002Fp>\u003Cp>To Mr. Yun Ma:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., FDA Establishment Identifier (FEI) 3043646847. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA has reviewed the records submitted from \u003Cstrong>(b)(4)\u003C\u002Fstrong> on your behalf in response to our May 1, 2026, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Additionally, the OTC drug product, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” is adulterated under section 501(a)(4)(A) as this drug product bears or contains a color additive that is unsafe within the meaning of section 721 of the FD&amp;C Act, 21 U.S.C. 379e. Accordingly, the introduction or delivery for introduction of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Cancelled Color Additive FD&amp;C Red No. 2\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on our review of drug product labels, the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” contains the color additive “CI 16185” (also known as FD&amp;C Red No. 2 or Amaranth). In 1976, FDA cancelled the certification and delisted FD&amp;C Red No. 2 because it could not be proven safe for use. Under 21 CFR 81.30(j)(1), using FD&amp;C Red No. 2 in drugs after January 28, 1976, results in the drug being adulterated.\u003C\u002Fp>\u003Cp>Any color additive not explicitly listed as safe for its intended use is deemed unsafe within the meaning of section 721(a) of the FD&amp;C Act. The inclusion of a delisted color additive in your drug product formulation indicates that your quality unit’s review (as required under 21 CFR 211.22) of your raw material qualification process and formulation review procedures is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information provided demonstrate that the quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of the drug manufacturing operations. The response includes discrepancies between the color additive on the labeling versus the batch formulation spreadsheet versus the color specified in the certificate of analysis (COA). For example, the labeling for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” listed “CI 16185” (also known as the cancelled color FD&amp;C Red No. 2) as the color additive. However, the separate formulation ingredient information provided listed a second color additive \u003Cstrong>(b)(4)\u003C\u002Fstrong> (also known as \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and the COA provided indicated a third distinct color additive, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>On July 28, 2026, the FDA sent an electronic request for additional information requesting clarification of these color additive discrepancies. This request went unanswered as did the follow-up electronic request sent on August 5, 2026.\u003C\u002Fp>\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your documentation to ensure you retain accurate records throughout your operation.\u003C\u002Fli>\u003Cli>A list of all products distributed in the United States in the last three years, with lot number, quantity shipped, and expiry dates. Identify the drug products you distributed.\u003C\u002Fli>\u003Cli>A list of your customers and addresses where the drug products were distributed.\u003C\u002Fli>\u003Cli>A copy of your quality agreement with the product owner, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A risk assessment to review all your drug formulations to ensure the use of appropriate color additives, including any that may use alternate names. For more information, see the webpage for Regulatory Status of Color Additives at https:\u002F\u002Fwww.hfpappexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=ColorAdditives.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in U.S. distribution, including customer notifications and recalls or market withdrawals.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Revocation of FD&amp;C Red No. 3\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA revoked the authorization for the use of FD&amp;C Red No. 3. We recommend manufacturers review their drug product formulations. Manufacturers who use FD&amp;C Red No. 3 in ingested drugs will have until January 18, 2028, to reformulate their products. For more information, see https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fhfp-constituent-updates\u002Ffda-revoke-authorization-use-red-no-3-food-and-ingested-drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., located at No. 3 Yiheng Road, Nanling Gongye Districtqinghu Ma Tian Street, Jiahe Street, Baiyun District, Guangzhou, Guangdong into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3043646847 and ATTN: Lynnsey Renn in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>FDA Listing\u003Cbr>US agent\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yun Ma\n\nRecipient Title\n\nProduct Manager\n\nGuangzhou Jiugong Research And Development Biotechnology Co., Ltd.\n\nNo. 3 Yiheng Road\n\nNanling Gongye Districtqinghu Ma Tian Street Jiahe Street\n\nBaiyun Qu\n\nGuangzhou Shi\n\nGuangdong Sheng, 510000\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 27, 2026\nWARNING LETTER\nReference number: 320-27-13\nTo Mr. Yun Ma:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., FDA Establishment Identifier (FEI) 3043646847. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the FDA as a manufacturer of over-the-counter (OTC) drug products, including (b)(4). FDA has reviewed the records submitted from (b)(4) on your behalf in response to our May 1, 2026, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\nAdditionally, the OTC drug product, “(b)(4),” is adulterated under section 501(a)(4)(A) as this drug product bears or contains a color additive that is unsafe within the meaning of section 721 of the FD&C Act, 21 U.S.C. 379e. Accordingly, the introduction or delivery for introduction of “(b)(4)” into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\nUse of Cancelled Color Additive FD&C Red No. 2\nBased on our review of drug product labels, the “(b)(4)” contains the color additive “CI 16185” (also known as FD&C Red No. 2 or Amaranth). In 1976, FDA cancelled the certification and delisted FD&C Red No. 2 because it could not be proven safe for use. Under 21 CFR 81.30(j)(1), using FD&C Red No. 2 in drugs after January 28, 1976, results in the drug being adulterated.\nAny color additive not explicitly listed as safe for its intended use is deemed unsafe within the meaning of section 721(a) of the FD&C Act. The inclusion of a delisted color additive in your drug product formulation indicates that your quality unit’s review (as required under 21 CFR 211.22) of your raw material qualification process and formulation review procedures is inadequate.\nYour firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nThe records and information provided demonstrate that the quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of the drug manufacturing operations. The response includes discrepancies between the color additive on the labeling versus the batch formulation spreadsheet versus the color specified in the certificate of analysis (COA). For example, the labeling for the “(b)(4)” listed “CI 16185” (also known as the cancelled color FD&C Red No. 2) as the color additive. However, the separate formulation ingredient information provided listed a second color additive (b)(4) (also known as (b)(4)) and the COA provided indicated a third distinct color additive, (b)(4).\nOn July 28, 2026, the FDA sent an electronic request for additional information requesting clarification of these color additive discrepancies. This request went unanswered as did the follow-up electronic request sent on August 5, 2026.\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive assessment of your documentation to ensure you retain accurate records throughout your operation.\nA list of all products distributed in the United States in the last three years, with lot number, quantity shipped, and expiry dates. Identify the drug products you distributed.\nA list of your customers and addresses where the drug products were distributed.\nA copy of your quality agreement with the product owner, (b)(4).\nA risk assessment to review all your drug formulations to ensure the use of appropriate color additives, including any that may use alternate names. For more information, see the webpage for Regulatory Status of Color Additives at https:\u002F\u002Fwww.hfpappexternal.fda.gov\u002Fscripts\u002Ffdcc\u002Findex.cfm?set=ColorAdditives.\nYour action plan to address any product quality or patient safety risks for batches of (b)(4) in U.S. distribution, including customer notifications and recalls or market withdrawals.\nResponsibilities as a Contractor\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nRevocation of FD&C Red No. 3\nFDA revoked the authorization for the use of FD&C Red No. 3. We recommend manufacturers review their drug product formulations. Manufacturers who use FD&C Red No. 3 in ingested drugs will have until January 18, 2028, to reformulate their products. For more information, see https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fhfp-constituent-updates\u002Ffda-revoke-authorization-use-red-no-3-food-and-ingested-drugs.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Guangzhou Jiugong Research And Development Biotechnology Co., Ltd., located at No. 3 Yiheng Road, Nanling Gongye Districtqinghu Ma Tian Street, Jiahe Street, Baiyun District, Guangzhou, Guangdong into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3043646847 and ATTN: Lynnsey Renn in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\nFDA Listing\nUS agent\n(b)(4)","Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.","guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026","2026-11-03","737769","Drugs Over-the-Counter Drugs","Mr. Yun Ma","2026-11-10T01:02:46.154+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-27",17,{"510k":344,"classification":345,"enforcement":346,"event":347,"event_backfill":348,"pma":349,"warning_letter":350},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]